The DOI matches its Crossref record; 276 of the 281 references it cites were found in a registry or an index; 22 of the 332 sources its claims cite were checked for support.
NAD+ metabolism and its roles in cellular processes during ageing
Open accessAbstract
Nicotinamide adenine dinucleotide (NAD+) is a coenzyme for redox reactions, making it central to energy metabolism. NAD+ is also an essential cofactor for non-redox NAD+-dependent enzymes, including sirtuins, CD38 and poly(ADP-ribose) polymerases. NAD+ can directly and indirectly influence many key cellular functions, including metabolic pathways, DNA repair, chromatin remodelling, cellular senescence and immune cell function. These cellular processes and functions are critical for maintaining tissue and metabolic homeostasis and for healthy ageing. Remarkably, ageing is accompanied by a gradual decline in tissue and cellular NAD+ levels in multiple model organisms, including rodents and humans. This decline in NAD+ levels is linked causally to numerous ageing-associated diseases, including cognitive decline, cancer, metabolic disease, sarcopenia and frailty. Many of these ageing-associated diseases can be slowed down and even reversed by restoring NAD+ levels. Therefore, targeting NAD+ metabolism has emerged as a potential therapeutic approach to ameliorate ageing-related disease, and extend the human healthspan and lifespan. However, much remains to be learnt about how NAD+ influences human health and ageing biology. This includes a deeper understanding of the molecular mechanisms that regulate NAD+ levels, how to effectively restore NAD+ levels during ageing, whether doing so is safe and whether NAD+ repletion will have beneficial effects in ageing humans.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
169 Not checked yet · 31 Own interpretation · 18 No basis given · 8 Supported · 5 Partly supported · 1 Own result · accuracy not yet measured
Every source the paper cites for this claim was checked and supports it.
In the paper
“On activation, PARP1 PARylates itself along with histones and other proteins that act as a scaffold to recruit and activate other DNA repair enzymes and proteins to the lesion site to initiate DNA repair30.”
§ NAD+ metabolism and its roles in cellular processes during ageing > Cellular NAD+ metabolism > NAD+ consumption routes
What the sources say
- Supportedcites [30] Ray Chaudhuri, A. & Nussenzweig, A. The multifaceted roles of PARP1 in DNA repair and chromatin remodelling. Nat. Rev. Mol. Cell Biol. 18, 610–621 (2017). source
The Biochemical activities of PARP1 section states that DNA damage stimulates PARP1 to add PAR chains to itself and to histone and non-histone proteins. It also says PAR-binding proteins are recruited to damage sites and that binding can activate their functional domains, supporting the described recruitment and activation mechanism. (LLM, conf=0.90)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The enzymatic activity of SARM1 (FIG. 2c) relies on the Toll/interleukin receptor (TIR) domain that was previously not known to possess catalytic activity and generally to be involved in protein–protein interaction59.”
§ NAD+ metabolism and its roles in cellular processes during ageing > Cellular NAD+ metabolism > NAD+ consumption routes
What the sources say
- Supportedcites [59] Essuman, K. et al. The SARM1 Toll/interleukin-1 receptor domain possesses intrinsic NAD cleavage activity that promotes pathological axonal degeneration. Neuron 93, 1334–1343.e5 (2017). This study demonstrates that SARM1 has both NAD+ glycohydrolase and cyclase activity, clarifying the key role of this enzyme in NAD+ depletion during Wallerian degeneration. source
The Introduction says neither SARM1 nor any TIR domain had previously been associated with enzymatic activity, describing TIR domains instead as signaling scaffolds. The Results section, “SARM1-TIR complex purified from mammalian cells cleaves NAD+,” links NAD+ degradation to the SARM1-TIR domain; the section “SARM1-TIR domain possesses intrinsic NAD+ cleavage activity” identifies SARM1 itself as the NADase. (LLM, conf=0.94)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Accordingly, NAD+ homeostasis is required for the proper function of various metabolic tissues, including fat, muscle, intestines, kidneys and liver (reviewed in72).”
§ NAD+ metabolism and its roles in cellular processes during ageing > NAD+-dependent mechanisms in ageing > Metabolic dysfunction
What the sources say
- Supportedcites [72] Katsyuba, E., Romani, M., Hofer, D. & Auwerx, J. NAD+ homeostasis in health and disease. Nat. Metab. 2, 9–31 (2020). source
The review links altered NAD+ homeostasis to disorders of skeletal muscle, intestine, liver and kidney, and reports functional benefits from restoring or preserving NAD+ in the intestine and liver (Fig. 4, p. 8). It also describes NAD+ regulation of adipocyte differentiation (NAD+ homeostasis and its maintenance, p. 5), supporting the inclusion of fat. (LLM, conf=0.88)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Blocking the NAM salvage pathway (BOX 1) in both M1 macrophages and M2 macrophages significantly reduced gene expression of select genes associated with the M1 and M2 phenotypes.”
§ NAD+ metabolism and its roles in cellular processes during ageing > NAD+-dependent mechanisms in ageing > Deregulation of immune cell function
What the sources say
- Supportedcites [45] Covarrubias, A. J. et al. Senescent cells promote tissue NAD+ decline during ageing via the activation of CD38+ macrophages. Nat. Metab. 2, 1265–1283 (2020). source
In the Results section, FK866 inhibition of NAMPT reduced mRNA levels of several M2 markers and suppressed mRNA levels of M1 inflammatory cytokines. The authors conclude that the NAM-salvage pathway regulates expression of a subset of M1 and M2 genes. No page number is provided in the supplied copy. (LLM, conf=0.93)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Recent observations suggest that innate immune cells, especially macrophages, may be the major cell population responding to the SASP with NAD+ degradation, thereby contributing to organism-wide decline in NAD+ levels45,105.”
§ NAD+ metabolism and its roles in cellular processes during ageing > NAD+-dependent mechanisms in ageing > Cellular senescence
What the sources say
- Supportedcites [45] Covarrubias, A. J. et al. Senescent cells promote tissue NAD+ decline during ageing via the activation of CD38+ macrophages. Nat. Metab. 2, 1265–1283 (2020). source
The Results section on ageing-associated adipose-tissue inflammation describes M1 macrophages as a possible key driver of age-related NAD loss. The Discussion says the SASP increases macrophage CD38 expression and NADase activity, and explicitly speculates that the mechanism may contribute to NAD decline in other tissues. That speculation matches the citing sentence’s qualified, organism-wide suggestion. (LLM, conf=0.85)
- Supportedcites [105] Chini, C. C. S. et al. CD38 ecto-enzyme in immune cells is induced during aging and regulates NAD+ and NMN levels. Nat. Metab. 2, 1284–1304 (2020). This study, along with Covarrubias et al. (2020), demonstrated that senescent cell burden is linked to tissue NAD+ level decline via CD38+ immune cells. source
The Results section on aging reports that M1 macrophages had the highest CD38-NADase activity among the immune cells tested. The Results sections on SASP and NMN availability report that factors from senescent cells increased macrophage CD38 activity and tissue NAD+ decline, and postulate that CD38+ immune cells modulate organismal NAD+ homeostasis by degrading extracellular NMN. The claim’s tentative wording matches that proposed mechanism; page numbers are not available in our copy. (LLM, conf=0.88)
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“we showed in ageing mouse models and mice treated with the senescence-inducing chemotherapeutic reagent doxorubicin that accumulation of senescent cells in metabolic tissues, such as the visceral fat and liver, can directly activate the expression of CD38 in tissue-resident macrophages45.”
§ NAD+ metabolism and its roles in cellular processes during ageing > NAD+-dependent mechanisms in ageing > Cellular senescence
What the sources say
- Supportedcites [45] Covarrubias, A. J. et al. Senescent cells promote tissue NAD+ decline during ageing via the activation of CD38+ macrophages. Nat. Metab. 2, 1265–1283 (2020). source
The Results section reports that senescent-cell accumulation in doxorubicin-treated mouse liver drives increased CD38 expression, which is reversed when senescent cells are removed (Fig. 6k). It also reports increased CD38 in resident macrophages of aged visceral fat and in Kupffer cells of aged liver, while doxorubicin treatment increases CD38-positive resident macrophages in visceral fat (Figs. 4e, 5d and 6g–i). (LLM, conf=0.90)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In ageing, declining NAD+ levels are associated with increased accumulation of proinflammatory M1-like resident macrophages in the liver and fat, which are characterized by increased expression of CD38 and heightened NADase activity45,105.”
§ NAD+ metabolism and its roles in cellular processes during ageing > NAD+-dependent mechanisms in ageing > Deregulation of immune cell function
What the sources say
- Supportedcites [45] Covarrubias, A. J. et al. Senescent cells promote tissue NAD+ decline during ageing via the activation of CD38+ macrophages. Nat. Metab. 2, 1265–1283 (2020). source
The Results sections on aged adipose tissue and Kupffer cells report declining NAD levels alongside increased CD38-positive resident macrophages in fat and pro-inflammatory M1-like Kupffer cells in liver. The Results also show that M1 macrophages express more CD38 and have enhanced CD38-dependent NADase activity. The findings are in mice. (LLM, conf=0.92)
- Partly supportedcites [105] Chini, C. C. S. et al. CD38 ecto-enzyme in immune cells is induced during aging and regulates NAD+ and NMN levels. Nat. Metab. 2, 1284–1304 (2020). This study, along with Covarrubias et al. (2020), demonstrated that senescent cell burden is linked to tissue NAD+ level decline via CD38+ immune cells. sourceExperimental — accuracy not yet measured
The Results section (‘Accumulation of CD38+ immune cells in tissues during aging’; page unavailable) reports more CD38+ macrophages/monocytes in the liver and white adipose tissue of aged mice, alongside increased CD38 expression per cell. It also reports higher NADase activity in M1 macrophages and in LPS-treated bone-marrow-derived macrophages from older mice. It does not establish that the accumulating macrophages in those tissues are resident M1-like cells or directly show heightened NADase activity in those tissue macrophages. (LLM, conf=0.86)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
None of the sources cited for this claim have been checked yet.
In the paper
“They sensitize tumours to DNA damage, but they have limited use due to toxicity223–225.”
§ NAD+ metabolism and its roles in cellular processes during ageing > Therapeutic targeting of NAD+ level decline > Inhibition of NAD+ consumption
What the sources say
- Could not verifycites [223] Alano, C. C. et al. NAD+ depletion is necessary and sufficient for poly(ADP-ribose) polymerase-1-mediated neuronal death. J. Neurosci. 30, 2967–2978 (2010). sourceExperimental — accuracy not yet measured
The Results section reports that PARP inhibitors blocked neuronal death in cortical neuron cultures, but does not discuss their clinical use. Searches for inhibitor toxicity, adverse effects, and clinical limitations found no passage addressing the claimed reason for limited use. (LLM, conf=0.75)
- Not checked yetcites [224] Almeida, G. S. et al. PARP inhibitor rucaparib induces changes in NAD levels in cells and liver tissues as assessed by MRS. NMR Biomed. https://doi.org/10.1002/nbm.3736 (2017). source
- Not checked yetcites [225] Mathews, M. T. & Berk, B. C. PARP-1 inhibition prevents oxidative and nitrosative stress-induced endothelial cell death via transactivation of the VEGF receptor 2. Arterioscler. Thromb. Vasc. Biol. 28, 711–717 (2008). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“78c also prevents age-related declines in NAD+ levels in mice, and treatment of aged mice with this compound was shown to ameliorate metabolic dysfunction, reduce DNA damage accumulation and improve muscle function91,231.”
§ NAD+ metabolism and its roles in cellular processes during ageing > Therapeutic targeting of NAD+ level decline > Inhibition of NAD+ consumption
What the sources say
- Supportedcites [91] Tarragó, M. G. et al. A potent and specific CD38 inhibitor ameliorates age-related metabolic dysfunction by reversing tissue NAD decline. Cell Metab. 27, 1081–1095.e10 (2018). This study demonstrates that the pharmacological inhibition of CD38 reverses age-related NAD+ level decline, improving several physiological and metabolic features. source
In the Results section on age-related cardiac dysfunction (page unavailable), 78c restored cardiac muscle NAD+ in aged mice to levels seen in young mice. The skeletal-muscle Results also report increased NAD+ in older mice treated with 78c. These findings support the claim that 78c counters age-related NAD+ decline in mice. (LLM, conf=0.90)
- Partly supportedcites [231] Boslett, J., Reddy, N., Alzarie, Y. A. & Zweier, J. L. Inhibition of CD38 with the thiazoloquin(az)olin(on)e 78c protects the heart against postischemic injury. J. Pharmacol. Exp. Ther. 369, 55–64 (2019). sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) reports a robust antiaging effect of 78c, and its cited Tarrago et al. study is described in the References as reversing age-related tissue NAD+ decline. This paper's own experiments, however, used 4–6-month-old mice and tested postischemic injury; it does not establish that 78c prevents age-related NAD+ decline in mice. (LLM, conf=0.82)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“SIRT3 mediates NMN-induced improvements in cardiac and extracardiac metabolic function in a mouse model of cardiomyopathy207.”
§ NAD+ metabolism and its roles in cellular processes during ageing > Therapeutic targeting of NAD+ level decline > Dietary supplementation
What the sources say
- Supportedcites [207] Martin, A. S. et al. Nicotinamide mononucleotide requires SIRT3 to improve cardiac function and bioenergetics in a Friedreich’s ataxia cardiomyopathy model. JCI Insight 2, e93885 (2017). source
The Introduction explicitly states that SIRT3 mediates NMN-induced improvements in both cardiac and extracardiac metabolic function in the FXN-KO mouse model. The section on whole-body energy expenditure also reports SIRT3-dependent decreases in systemic and cardiac glucose utilization following NMN treatment. (LLM, conf=0.94)
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
- It may state two separate claims as one. 96
- Probably not a substantial claim. 16
Every source the paper cites for this claim was checked and supports it.
In the paper
“However, since PARP1 has lower Km and higher Vmax with regard to NAD+ than SIRT1, PARP1 likely outcompetes SIRT1 for NAD+ as a result of its greater binding affinity and faster kinetics34.”
§ NAD+ metabolism and its roles in cellular processes during ageing > Cellular NAD+ metabolism > NAD+ consumption routes
What the sources say
- Supportedcites [34] Cantó, C., Sauve, A. A. & Bai, P. Crosstalk between poly(ADP-ribose) polymerase and sirtuin enzymes. Mol. Asp. Med. 34, 1168–1201 (2013). source
Section 2.2 states that PARP-1 has a fivefold lower Km and a much stronger Vmax than SIRT1, supporting the cited sentence’s proposed advantage in competing for NAD+. Section 2.1 also describes competition for a limited NAD+ pool. The verbatim citing sentence does not make the additional same-compartment assertion included in the supplied paraphrase. (LLM, conf=0.91)
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Although this observation was initially disregarded, there is now growing evidence that ageing not only leads to increased macrophage abundance but is also accompanied by altered macrophage polarization state and function, which is emerging as a key driver of inflammageing98,99.”
§ NAD+ metabolism and its roles in cellular processes during ageing > NAD+-dependent mechanisms in ageing > Deregulation of immune cell function
What the sources say
- Partly supportedcites [98] Oishi, Y. & Manabe, I. Macrophages in age-related chronic inflammatory diseases. NPJ Aging Mech. Dis. 2, 16018 (2016). sourceExperimental — accuracy not yet measured
The ‘Macrophage lineage cells in metabolic control’ section reports a shift toward proinflammatory M1 macrophages in aged mouse visceral fat and higher cytokine expression, while the ‘Perspectives’ section links changes in macrophage phenotype and function to inflammaging. Those passages support the polarization and function parts of the claim, but the retrieved passages do not establish a general increase in macrophage abundance with age; the reported increase in visceral-fat cell numbers concerns T cells. (LLM, conf=0.85)
- Not checked yetcites [99] van Beek, A. A., Van den Bossche, J., Mastroberardino, P. G., de Winther, M. P. J. & Leenen, P. J. M. Metabolic alterations in aging macrophages: ingredients for inflammaging? Trends Immunol. 40, 113–127 (2019). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Additionally, higher NAD+ levels can promote the deacetylase and deacylase activity of both nuclear SIRT1 and mitochondrial SIRT3, which regulate mitochondrial function and protect from high-fat diet-induced metabolic disease42,81,85–88.”
§ NAD+ metabolism and its roles in cellular processes during ageing > NAD+-dependent mechanisms in ageing > Metabolic dysfunction
What the sources say
- Not checked yetcites [42] Camacho-Pereira, J. et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metab. 23, 1127–1139 (2016). This study demonstrates that CD38 expression increases in multiple tissues during aging and that CD38 is a major NADase involved in the ageing-related tissue decline of NAD+ levels. source
- Partly supportedcites [81] Cantó, C. et al. The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab. 15, 838–847 (2012). sourceExperimental — accuracy not yet measured
The Results (‘NR enhances sirtuin activity in vivo’; page unavailable) report increased NAD+ alongside deacetylation of SIRT1 and SIRT3 targets in tissues where NAD+ rose. The Discussion links NR-driven NAD+ increases to activity in nuclear and mitochondrial compartments, and the Results link this tissue-specific response to mitochondrial function and protection against metabolic damage. The paper does not establish deacylase activity beyond deacetylation, so that additional part of the claim is unsupported. (LLM, conf=0.86)
- Partly supportedcites [85] Hirschey, M. D. et al. SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation. Nature 464, 121–125 (2010). sourceExperimental — accuracy not yet measured
The paper’s Abstract says SIRT3 requires NAD+ and would be more active at a high NAD+/NADH ratio; it also reports that SIRT3 deacetylates LCAD and regulates mitochondrial fatty-acid oxidation during fasting. It does not establish SIRT1 activity, deacylase activity, or protection from high-fat diet-induced metabolic disease. (LLM, conf=0.87)
- Partly supportedcites [86] Hirschey, M. D. et al. SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the development of the metabolic syndrome. Mol. Cell 44, 177–190 (2011). sourceExperimental — accuracy not yet measured
The Introduction (page not provided) identifies sirtuins as NAD+-dependent deacetylases and SIRT3 as mitochondrial. The Results report NAD+-dependent SIRT3 deacetylase activity, while the Discussion links SIRT3 loss to worse high-fat-diet metabolic outcomes. The paper does not establish the claimed effects of higher NAD+ levels on SIRT1, address deacylase activity, or show that raising NAD+ protects against metabolic disease. (LLM, conf=0.88)
- Partly supportedcites [87] Lagouge, M. et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 127, 1109–1122 (2006). sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) reports that resveratrol facilitates SIRT1-mediated deacetylation, improves mitochondrial function, and protects mice on a high-fat diet from obesity and insulin resistance. It does not establish that higher NAD+ levels produce those effects, or address mitochondrial SIRT3 or deacylase activity. (LLM, conf=0.88)
- Not checked yetcites [88] Pfluger, P. T., Herranz, D., Velasco-Miguel, S., Serrano, M. & Tschöp, M. H. Sirt1 protects against high-fat diet-induced metabolic damage. Proc. Natl Acad. Sci. USA 105, 9793–9798 (2008). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Ageing is associated with increased activation of the NLRP3 inflammasome45,107, which is primarily expressed by myeloid immune cells107,108, and a subsequent increase in the expression of IL-1β, which is a major cytokine implicated in promoting ageing-related disease107.”
§ NAD+ metabolism and its roles in cellular processes during ageing > NAD+-dependent mechanisms in ageing > Deregulation of immune cell function
What the sources say
- Partly supportedcites [45] Covarrubias, A. J. et al. Senescent cells promote tissue NAD+ decline during ageing via the activation of CD38+ macrophages. Nat. Metab. 2, 1265–1283 (2020). sourceExperimental — accuracy not yet measured
The Results section on ageing adipose tissue reports increased Il1b mRNA and greater inflammasome activation in old mice, indicated by processed caspase-1. It does not identify that inflammasome as NLRP3, establish that NLRP3 is primarily expressed by myeloid immune cells, or show that its activation caused the increase in Il1b. The cited passage also does not link IL-1β specifically to ageing-related disease. (LLM, conf=0.88)
- Supportedcites [107] Youm, Y.-H. et al. Canonical Nlrp3 inflammasome links systemic low-grade inflammation to functional decline in aging. Cell Metab. 18, 519–532 (2013). source
The Results sections report age-related Nlrp3-dependent caspase-1 activation and increased IL-1β expression in adipose tissue and the hippocampus. The CNS Results section also states that the inflammasome is expressed in myeloid-lineage cells; the Introduction links IL-1 to age-related degenerative disease. Page numbers are unavailable in our copy. (LLM, conf=0.89)
- Could not verifycites [108] Tabula Muris Consortium et al. Single-cell transcriptomics of 20 mouse organs creates a Tabula Muris. Nature 562, 367–372 (2018). This is a compendium of single-cell transcriptomic data that comprises more than 100,000 cells from 20 mouse organs and tissues. sourceExperimental — accuracy not yet measured
The Abstract describes a single-cell dataset from 3-month-old mice, not an analysis of ageing. Searches for NLRP3, myeloid-cell expression, and IL-1β found no passage in our copy addressing the claimed inflammasome activation or subsequent cytokine increase. (LLM, conf=0.76)
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Partly supported
In the paper
“We showed that macrophages co-cultured in or exposed to conditioned media from senescent cells have enhanced expression of the NAD+-consuming enzyme CD38 and increased proliferation45.”
§ NAD+ metabolism and its roles in cellular processes during ageing > NAD+-dependent mechanisms in ageing > Cellular senescence
What the sources say
- Not checked yetcites [45] Covarrubias, A. J. et al. Senescent cells promote tissue NAD+ decline during ageing via the activation of CD38+ macrophages. Nat. Metab. 2, 1265–1283 (2020). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“However, during ageing, this balance between catabolic and anabolic processes can shift, and NAD+ degradation can outpace the ability of cells to make NAD+ de novo or their ability to effectively recycle or salvage NAM.”
§ NAD+ metabolism and its roles in cellular processes during ageing > Cellular NAD+ metabolism
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Briefly, the PARP-mediated cleavage of NAD+ produces NAM and ADP-ribose as by-products, in which ADP-ribose is added as single or covalently linked polymers to PARP itself and other acceptor proteins, in a process called ‘poly(ADP-ribosyl)ation’ (PARylation) (FIG. 2b).”
§ NAD+ metabolism and its roles in cellular processes during ageing > Cellular NAD+ metabolism > NAD+ consumption routes
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Among all the PARPs, only PARP1, PARP2 and PARP3 localize to the nucleus (FIG. 1b) in response to early DNA damage and have a key role in DNA damage repair25–27 (Supplementary Box 2).”
§ NAD+ metabolism and its roles in cellular processes during ageing > Cellular NAD+ metabolism > NAD+ consumption routes
What the sources say
- Not checked yetcites [25] Bai, P. & Cantó, C. The role of PARP-1 and PARP-2 enzymes in metabolic regulation and disease. Cell Metab. 16, 290–295 (2012). source
- Not checked yetcites [26] Oliver, A. W. et al. Crystal structure of the catalytic fragment of murine poly(ADP-ribose) polymerase-2. Nucleic Acids Res. 32, 456–464 (2004). source
- Not checked yetcites [27] Boehler, C. et al. Poly(ADP-ribose) polymerase 3 (PARP3), a newcomer in cellular response to DNA damage and mitotic progression. Proc. Natl Acad. Sci. USA 108, 2783–2788 (2011). source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Early studies in yeast demonstrated roles of sirtuins in gene silencing, which in 2000 was attributed to their activity as NAD+-dependent deacetylases12.”
§ NAD+ metabolism and its roles in cellular processes during ageing > Cellular NAD+ metabolism > NAD+ consumption routes
What the sources say
- Not checked yetcites [12] Imai, S., Armstrong, C. M., Kaeberlein, M. & Guarente, L. Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase. Nature 403, 795–800 (2000). This study is the first to demonstrates that sirtuin function is dependent on NAD+. source
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“The human PARP protein family is composed of 17 proteins characterized by poly(ADP-ribosyl) polymerase or mono(ADP-ribosyl) polymerase activity24.”
§ NAD+ metabolism and its roles in cellular processes during ageing > Cellular NAD+ metabolism > NAD+ consumption routes
What the sources say
- Not checked yetcites [24] Hottiger, M. O., Hassa, P. O., Lüscher, B., Schüler, H. & Koch-Nolte, F. Toward a unified nomenclature for mammalian ADP-ribosyltransferases. Trends Biochem. Sci. 35, 208–219 (2010). source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Thus, besides the liver, the de novo biosynthetic pathway seems to be a more indirect mechanism contributing to system-wide NAD+ levels, with most NAD+ coming from the NAM salvage pathway (BOX 1).”
§ NAD+ metabolism and its roles in cellular processes during ageing > Cellular NAD+ metabolism > NAD+ biosynthetic pathways
What the sources say
- Not checked yetcites [5] Liu, L. et al. Quantitative analysis of NAD synthesis-breakdown fluxes. Cell Metab. 27, 1067–1080.e5 (2018). This study demonstrates that NAD+ synthesis breakdown fluxes differ widely across tissues, suggesting a tissue-specific NAD+ metabolism. source
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“While enhancing the activation of sirtuins has emerged as a way to increase lifespan and healthspan, aberrant activation of PARPs and NAD+ glycohydrolases, such as CD38, may exert the opposite effect and exacerbate ageing phenotypes (see later).”
§ NAD+ metabolism and its roles in cellular processes during ageing > Cellular NAD+ metabolism
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“In apparent contrast with its role in promoting mitochondrial biogenesis through peroxisome proliferator-activated receptor-γ co-activator 1α deacetylation19–21, SIRT1 has also been implicated in turnover of defective mitochondria by mitophagy22,23.”
§ NAD+ metabolism and its roles in cellular processes during ageing > Cellular NAD+ metabolism > NAD+ consumption routes
What the sources say
- Not checked yetcites [19] Amat, R. et al. SIRT1 controls the transcription of the peroxisome proliferator-activated receptor-γ co-activator-1α (PGC-1α) gene in skeletal muscle through the PGC-1α Autoregulatory Loop and Interaction with MyoD. J. Biol. Chem. 284, 21872–21880 (2009). source
- Not checked yetcites [20] Nemoto, S., Fergusson, M. M. & Finkel, T. SIRT1 functionally interacts with the metabolic regulator and transcriptional coactivator PGC-1α. J. Biol. Chem. 280, 16456–16460 (2005). source
- Not checked yetcites [21] Gurd, B. J. Deacetylation of PGC-1α by SIRT1: importance for skeletal muscle function and exercise-induced mitochondrial biogenesis. Appl. Physiol. Nutr. Metab. 36, 589–597 (2011). source
- Not checked yetcites [22] Kang, H. T. & Hwang, E. S. Nicotinamide enhances mitochondria quality through autophagy activation in human cells. Aging Cell 8, 426–438 (2009). source
- Not checked yetcites [23] Jang, S.-Y., Kang, H. T. & Hwang, E. S. Nicotinamide-induced mitophagy: event mediated by high NAD+/NADH ratio and SIRT1 protein activation. J. Biol. Chem. 287, 19304–19314 (2012). source
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Most tryptophan is metabolized to NAM in the liver, where it is released into the serum, taken up by peripheral cells and converted to NAD+ by the NAM salvage pathway5.”
§ NAD+ metabolism and its roles in cellular processes during ageing > Cellular NAD+ metabolism > NAD+ biosynthetic pathways
What the sources say
- Not checked yetcites [5] Liu, L. et al. Quantitative analysis of NAD synthesis-breakdown fluxes. Cell Metab. 27, 1067–1080.e5 (2018). This study demonstrates that NAD+ synthesis breakdown fluxes differ widely across tissues, suggesting a tissue-specific NAD+ metabolism. source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Specifically, recent evidence has shown that nuclear SIRT1, SIRT6 and SIRT7 are critical regulators of DNA repair and genome stability and that mitochondrial SIRT3, SIRT4 and SIRT5 and nuclear SIRT1 regulate mitochondrial homeostasis and metabolism7.”
§ NAD+ metabolism and its roles in cellular processes during ageing > Cellular NAD+ metabolism > NAD+ consumption routes
What the sources say
- Not checked yetcites [7] Carrico, C., Meyer, J. G., He, W., Gibson, B. W. & Verdin, E. The mitochondrial acylome emerges: proteomics, regulation by sirtuins, and metabolic and disease implications. Cell Metab. 27, 497–512 (2018). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“NAD+ can be made de novo from l-tryptophan via the kynurenine pathway or from vitamin precursors, such as nicotinic acid (NA), via the Preiss–Handler pathway (FIG. 1a).”
§ NAD+ metabolism and its roles in cellular processes during ageing > Cellular NAD+ metabolism > NAD+ biosynthetic pathways
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“In addition, SIRT1 and a key enzyme of the NAD+ salvage pathway, nicotinamide phosphoribosyltransferase (NAMPT) (BOX 1), are key players in the circadian regulation of NAD+ levels, and NAMPT is regulated by the circadian clock, which provides a feedback loop, resulting in circadian oscillation of NAD+ levels10,11.”
§ NAD+ metabolism and its roles in cellular processes during ageing > Cellular NAD+ metabolism > NAD+ consumption routes
What the sources say
- Not checked yetcites [10] Ramsey, K. M. et al. Circadian clock feedback cycle through NAMPT-mediated NAD+ biosynthesis. Science 324, 651–654 (2009). source
- Not checked yetcites [11] Nakahata, Y., Sahar, S., Astarita, G., Kaluzova, M. & Sassone-Corsi, P. Circadian control of the NAD+ salvage pathway by CLOCK-SIRT1. Science 324, 654–657 (2009). This study demonstrates that intracellular NAD+ levels are regulated by the core circadian regulator CLOCK–BMAL1 through the modulation of NAMPT expression. source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Additionally, some cells, mostly in the liver, can synthesize NAD+ de novo from multiple dietary sources.”
§ NAD+ metabolism and its roles in cellular processes during ageing > Cellular NAD+ metabolism
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: fails — The paper may give no reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. The paper may give no reason why it holds.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Therefore, targeting NAD+ metabolism has emerged as a potential therapeutic approach to ameliorate ageing-related disease, and extend the human healthspan and lifespan.”
§ NAD+ metabolism and its roles in cellular processes during ageing > Abstract
plainconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Some of these critical cellular processes include metabolic pathways, redox homeostasis, maintenance and repair of DNA to safeguard genomic stability, epigenetic regulation and chromatin remodelling, and autophagy.”
§ NAD+ metabolism and its roles in cellular processes during ageing > Cellular NAD+ metabolism > Cellular roles of NAD+
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Accordingly, NAD+ is a mediator of key cellular functions and adaptation to metabolic needs.”
§ NAD+ metabolism and its roles in cellular processes during ageing > Cellular NAD+ metabolism > Cellular roles of NAD+
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“PARP3 is important in DNA repair as well27, suggesting a large overlap and potential redundancy in PARP1, PARP2 and PARP3.”
§ NAD+ metabolism and its roles in cellular processes during ageing > Cellular NAD+ metabolism > NAD+ consumption routes
What the sources say
- Not checked yetcites [27] Boehler, C. et al. Poly(ADP-ribose) polymerase 3 (PARP3), a newcomer in cellular response to DNA damage and mitotic progression. Proc. Natl Acad. Sci. USA 108, 2783–2788 (2011). source
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“CD38 also performs a base-exchange reaction, by swapping the NAM of NAD(P)+ for NA in acidic conditions and generating nicotinic acid adenine dinucleotide (phosphate) (NAAD(P))37 (FIG. 2c).”
§ NAD+ metabolism and its roles in cellular processes during ageing > Cellular NAD+ metabolism > NAD+ consumption routes
What the sources say
- Not checked yetcites [37] Liu, Q., Kriksunov, I. A., Hao, Q., Graeff, R. & Lee, H. C. Acidic residues at the active sites of CD38 and ADP-ribosyl cyclase determine NAAPD synthesis and hydrolysis activities. J. Biol. Chem. https://doi.org/10.2210/pdb2hct/pdb (2006). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“SARM1 was only very recently assigned to the NAD+ glycohydrolase and cyclase family along with CD38 and CD157.”
§ NAD+ metabolism and its roles in cellular processes during ageing > Cellular NAD+ metabolism > NAD+ consumption routes
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“The CD38–CD31 axis seems to promote a proliferative response in chronic lymphocytic leukaemia lymphocytes, suggesting a detrimental role of CD38 in blood cancers53,54 (see Supplementary Box 3).”
§ NAD+ metabolism and its roles in cellular processes during ageing > Cellular NAD+ metabolism > NAD+ consumption routes
What the sources say
- Not checked yetcites [53] Vallario, A. et al. Human myeloma cells express the CD38 ligand CD31. Br. J. Haematol. 105, 441–444 (1999). source
- Not checked yetcites [54] Deaglio, S. et al. CD38/CD31 interactions activate genetic pathways leading to proliferation and migration in chronic lymphocytic leukemia cells. Mol. Med. 16, 87–91 (2010). source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The glycohydrolysis of NAD+ is the primary catalytic reaction that cleaves the glycosidic bond within NAD+ to generate NAM and ADP-ribose, whereas the ADP-ribosyl cyclase activity generates cyclic ADP-ribose (FIG. 2c).”
§ NAD+ metabolism and its roles in cellular processes during ageing > Cellular NAD+ metabolism > NAD+ consumption routes
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Despite its controversial role in immune cells, SARM1 plays an undisputed key role in axonal degeneration and is emerging as a therapeutic target to prevent or ameliorate neurodegenerative diseases and traumatic brain injuries (as discussed in the section Neurodegeneration).”
§ NAD+ metabolism and its roles in cellular processes during ageing > Cellular NAD+ metabolism > NAD+ consumption routes
What the sources say
- Not checked yetcites [60] Gerdts, J., Brace, E. J., Sasaki, Y., DiAntonio, A. & Milbrandt, J. SARM1 activation triggers axon degeneration locally via NAD destruction. Science 348, 453–457 (2015). source
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“SARM1 is primarily expressed in neurons and promotes neuronal morphogenesis and inflammation61,62; however, SARM1 is also expressed by immune cells such as macrophages and T lymphocytes, and regulates their functions63–65.”
§ NAD+ metabolism and its roles in cellular processes during ageing > Cellular NAD+ metabolism > NAD+ consumption routes
What the sources say
- Not checked yetcites [61] Wang, Q. et al. Sarm1/Myd88-5 regulates neuronal intrinsic immune response to traumatic axonal injuries. Cell Rep. 23, 716–724 (2018). source
- Not checked yetcites [62] Lin, C.-W., Chen, C.-Y., Cheng, S.-J., Hu, H.-T. & Hsueh, Y.-P. Sarm1 deficiency impairs synaptic function and leads to behavioral deficits, which can be ameliorated by an mGluR allosteric modulator. Front. Cell. Neurosci. 8, 87 (2014).
- Not checked yetcites [63] Carty, M. et al. The human adaptor SARM negatively regulates adaptor protein TRIF-dependent Toll-like receptor signaling. Nat. Immunol. 7, 1074–1081 (2006). source
- Not checked yetcites [64] Panneerselvam, P. et al. T-cell death following immune activation is mediated by mitochondria-localized SARM. Cell Death Differ. 20, 478–489 (2013). source
- Not checked yetcites [65] Zhao, Z. Y. et al. A cell-permeant mimetic of NMN activates SARM1 to produce cyclic ADP-ribose and induce non-apoptotic cell death. iScience 15, 452–466 (2019). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“However, recent evidence shows that, like CD38, CD157 is upregulated in ageing tissues45 and may have a role in ageing-related diseases, such as rheumatoid arthritis and cancer46.”
§ NAD+ metabolism and its roles in cellular processes during ageing > Cellular NAD+ metabolism > NAD+ consumption routes
What the sources say
- Not checked yetcites [45] Covarrubias, A. J. et al. Senescent cells promote tissue NAD+ decline during ageing via the activation of CD38+ macrophages. Nat. Metab. 2, 1265–1283 (2020). source
- Not checked yetcites [46] Ortolan, E., Augeri, S., Fissolo, G., Musso, I. & Funaro, A. CD157: from immunoregulatory protein to potential therapeutic target. Immunol. Lett. 205, 59–64 (2019). source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“SARM1 was originally discovered as a negative regulator of the innate immune response via direct interaction with TRIF (TIR domain-containing adapter protein inducing interferon-β), downstream of Toll-like receptor signalling63.”
§ NAD+ metabolism and its roles in cellular processes during ageing > Cellular NAD+ metabolism > NAD+ consumption routes
What the sources say
- Not checked yetcites [63] Carty, M. et al. The human adaptor SARM negatively regulates adaptor protein TRIF-dependent Toll-like receptor signaling. Nat. Immunol. 7, 1074–1081 (2006). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“Importantly, other than NAD+ and NADP+, NMN is emerging as an alternative substrate of CD38 (REFS41,42), whereas CD157 consumes NR as an alternative substrate43,44 (FIG. 2c).”
§ NAD+ metabolism and its roles in cellular processes during ageing > Cellular NAD+ metabolism > NAD+ consumption routes
What the sources say
- Not checked yetcites [41] Torti, M., Bertoni, A., Canobbio, I., Sinigaglia, F. & Balduini, C. Hydrolysis of NADP by platelet CD38 in the absence of synthesis and degradation of cyclic ADP-ribose 2′-phosphate. FEBS Lett. 455, 359–363 (1999). source
- Not checked yetcites [42] Camacho-Pereira, J. et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metab. 23, 1127–1139 (2016). This study demonstrates that CD38 expression increases in multiple tissues during aging and that CD38 is a major NADase involved in the ageing-related tissue decline of NAD+ levels. source
- Not checked yetcites [43] Aomatsu, E. et al. Novel SCRG1/BST1 axis regulates self-renewal, migration, and osteogenic differentiation potential in mesenchymal stem cells. Sci. Rep. 4, 3652 (2014). source
- Not checked yetcites [44] Preugschat, F. et al. A pre-steady state and steady state kinetic analysis of the N-ribosyl hydrolase activity of hCD157. Arch. Biochem. Biophys. 564, 156–163 (2014). source
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“CD38 is a transmembrane protein with a type ii orientation and/or a type III orientation identified in the late 1970s as a T cell activation marker but now known to be ubiquitously expressed, particularly during inflammation47,48.”
§ NAD+ metabolism and its roles in cellular processes during ageing > Cellular NAD+ metabolism > NAD+ consumption routes
What the sources say
- Not checked yetcites [47] Reinherz, E. L., Kung, P. C., Goldstein, G., Levey, R. H. & Schlossman, S. F. Discrete stages of human intrathymic differentiation: analysis of normal thymocytes and leukemic lymphoblasts of T-cell lineage. Proc. Natl Acad. Sci. USA 77, 1588–1592 (1980). source
- Not checked yetcites [48] Shubinsky, G. & Schlesinger, M. The CD38 lymphocyte differentiation marker: new insight into its ectoenzymatic activity and its role as a signal transducer. Immunity 7, 315–324 (1997). source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“Several lines of evidence suggest that CD157 activation by specific monoclonal antibodies promotes trafficking of neutrophils and monocytes58.”
§ NAD+ metabolism and its roles in cellular processes during ageing > Cellular NAD+ metabolism > NAD+ consumption routes
What the sources say
- Not checked yetcites [58] Funaro, A. et al. CD157 is an important mediator of neutrophil adhesion and migration. Blood 104, 4269–4278 (2004). source
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“CD157 is a glycophosphatidylinositol-anchored protein, which was first identified in the myeloid compartment of the haematopoietic system49. However, CD157 is also expressed by other cells, including B cell progenitors, Paneth cells and endothelial cells in the gut, pancreas and kidney50.”
§ NAD+ metabolism and its roles in cellular processes during ageing > Cellular NAD+ metabolism > NAD+ consumption routes
What the sources say
- Not checked yetcites [49] Todd, R. F. 3rd, Roach, J. A. & Arnaout, M. A. The modulated expression of Mo5, a human myelomonocytic plasma membrane antigen. Blood 65, 964–973 (1985).
- Not checked yetcites [50] Quarona, V. et al. CD38 and CD157: a long journey from activation markers to multifunctional molecules. Cytometry B Clin. Cytom. 84, 207–217 (2013). source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Although SARM1 was originally reported to be required for chemokine CCL5 production in macrophages66, recent evidence revealed that SARM1 is not expressed in macrophages and that the observed chemokine phenotype was due to a background effect of the Sarm1-knockout mouse strain67.”
§ NAD+ metabolism and its roles in cellular processes during ageing > Cellular NAD+ metabolism > NAD+ consumption routes
What the sources say
- Not checked yetcites [66] Gürtler, C. et al. SARM regulates CCL5 production in macrophages by promoting the recruitment of transcription factors and RNA polymerase II to the Ccl5 promoter. J. Immunol. 192, 4821–4832 (2014). source
- Not checked yetcites [67] Uccellini, M. B. et al. Passenger mutations confound phenotypes of SARM1-deficient mice. Cell Rep. 31, 107498 (2020). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Of note, cyclic ADP-ribose, NAAD(P) and ADP-ribose are all key Ca2+-mobilizing second messengers, illustrating the pivotal role of CD38 in activating Ca2+ signalling and modulating essential cell processes, such as immune cell activation, survival and metabolism38–40.”
§ NAD+ metabolism and its roles in cellular processes during ageing > Cellular NAD+ metabolism > NAD+ consumption routes
What the sources say
- Not checked yetcites [38] Ernst, I. M. A., Fliegert, R. & Guse, A. H. Adenine dinucleotide second messengers and T-lymphocyte calcium signaling. Front. Immunol. 4, 259 (2013).
- Not checked yetcites [39] Yu, P. et al. Direct gating of the TRPM2 channel by cADPR via specific interactions with the ADPR binding pocket. Cell Rep. 27, 3684–3695.e4 (2019). source
- Not checked yetcites [40] Mao, S. Architecture of the human TRPM2 channel. Science 362, 1372.12–1374 (2018). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“For example, CD38 is an adhesion receptor interacting with CD31 to mediate immune cell trafficking and extravasation through the endothelium51,52.”
§ NAD+ metabolism and its roles in cellular processes during ageing > Cellular NAD+ metabolism > NAD+ consumption routes
What the sources say
- Not checked yetcites [51] Deaglio, S. et al. Human CD38 (ADP-ribosyl cyclase) is a counter-receptor of CD31, an Ig superfamily member. J. Immunol. 160, 395–402 (1998). source
- Not checked yetcites [52] Deaglio, S. et al. Human CD38 and its ligand CD31 define a unique lamina propria T lymphocyte signaling pathway. FASEB J. 15, 580–582 (2001). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“Like Parp1-knockout mice, Parp2-knockout mice show enhanced SIRT1 activity and improved metabolic function, and are protected from high-fat diet-induced obesity36.”
§ NAD+ metabolism and its roles in cellular processes during ageing > Cellular NAD+ metabolism > NAD+ consumption routes
What the sources say
- Not checked yetcites [36] Bai, P. et al. PARP-2 regulates SIRT1 expression and whole-body energy expenditure. Cell Metab. 13, 450–460 (2011). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“For example, in mice fed a high-fat diet, those that were treated with PARP inhibitors or lacking PARP1 and PARP2 had increased NAD+ levels, increased SIRT1 activity and improved mitochondrial function, and were protected from insulin resistance31,32.”
§ NAD+ metabolism and its roles in cellular processes during ageing > Cellular NAD+ metabolism > NAD+ consumption routes
What the sources say
- Not checked yetcites [31] Bai, P. et al. PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation. Cell Metab. 13, 461–468 (2011). source
- Not checked yetcites [32] Pirinen, E. et al. Pharmacological inhibition of poly(ADP-ribose) polymerases improves fitness and mitochondrial function in skeletal muscle. Cell Metab. 19, 1034–1041 (2014). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“PARP2 is structurally related to PARP1. They share a similar catalytic domain required for several cellular processes, including DNA repair and transcriptional regulation, and account for about 10% of PARP activity35.”
§ NAD+ metabolism and its roles in cellular processes during ageing > Cellular NAD+ metabolism > NAD+ consumption routes
What the sources say
- Not checked yetcites [35] Gui, B. et al. Selective targeting of PARP-2 inhibits androgen receptor signaling and prostate cancer growth through disruption of FOXA1 function. Proc. Natl Acad. Sci. USA 116, 14573–14582 (2019). source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Moreover, CD157 interacts with integrins to form a receptor recognized by scrapie-responsive gene 1 protein (SCRG1), promoting self-renewal, migration and osteogenic differentiation of human mesenchymal stem cells43.”
§ NAD+ metabolism and its roles in cellular processes during ageing > Cellular NAD+ metabolism > NAD+ consumption routes
What the sources say
- Not checked yetcites [43] Aomatsu, E. et al. Novel SCRG1/BST1 axis regulates self-renewal, migration, and osteogenic differentiation potential in mesenchymal stem cells. Sci. Rep. 4, 3652 (2014). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Unfortunately, while NR could effectively increase NAD+ levels in these individuals94, participants in neither study showed any signs of weight loss, increased insulin sensitivity or enhanced mitochondrial function, among other metabolic parameters studied.”
§ NAD+ metabolism and its roles in cellular processes during ageing > NAD+-dependent mechanisms in ageing > Metabolic dysfunction
What the sources say
- Not checked yetcites [93] Dollerup, O. L. et al. Effects of nicotinamide riboside on endocrine pancreatic function and incretin hormones in nondiabetic men with obesity. J. Clin. Endocrinol. Metab. 104, 5703–5714 (2019). source
- Not checked yetcites [94] Remie, C. M. E. et al. Nicotinamide riboside supplementation alters body composition and skeletal muscle acetylcarnitine concentrations in healthy obese humans. Am. J. Clin. Nutr. https://doi.org/10.1093/ajcn/nqaa072 (2020). source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Accordingly, obesity accelerates and exacerbates ageing, and has been associated with shortened lifespan71.”
§ NAD+ metabolism and its roles in cellular processes during ageing > NAD+-dependent mechanisms in ageing > Metabolic dysfunction
What the sources say
- Not checked yetcites [71] Salvestrini, V., Sell, C. & Lorenzini, A. Obesity may accelerate the aging process. Front. Endocrinol. 10, 266 (2019). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“inhibition of NAMPT and subsequent depletion of NAD+ pools in macrophages decreased the secretion of proinflammatory cytokines, such as TNF, and caused morphological changes, such as reduced spreading in these cells100,101”
§ NAD+ metabolism and its roles in cellular processes during ageing > NAD+-dependent mechanisms in ageing > Deregulation of immune cell function
What the sources say
- Not checked yetcites [100] Van Gool, F. et al. Intracellular NAD levels regulate tumor necrosis factor protein synthesis in a sirtuin-dependent manner. Nat. Med. 15, 206–210 (2009). This study is one of the first to demonstrate that NAD+ levels can influence innate immune cell function. source
- Not checked yetcites [101] Venter, G. et al. NAMPT-mediated salvage synthesis of NAD+ controls morphofunctional changes of macrophages. PLoS ONE 9, e97378 (2014).
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“In line with this mechanism, mice with adipocyte-specific deletion of NAMPT have lower levels of NAD+ in their fat tissues, increased insulin resistance and increased metabolic dysfunction, which can be rescued with NMN supplementation92.”
§ NAD+ metabolism and its roles in cellular processes during ageing > NAD+-dependent mechanisms in ageing > Metabolic dysfunction
What the sources say
- Not checked yetcites [92] Stromsdorfer, K. L. et al. NAMPT-mediated NAD+ biosynthesis in adipocytes regulates adipose tissue function and multi-organ insulin sensitivity in mice. Cell Rep. 16, 1851–1860 (2016). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“We now know that NAD+ lies at the heart of metabolism and regulates metabolic flux of multiple metabolic pathways (for details see BOX 1 and Supplementary Box 2).”
§ NAD+ metabolism and its roles in cellular processes during ageing > NAD+-dependent mechanisms in ageing > Metabolic dysfunction
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Inflammageing is now being recognized as a hallmark of ageing and a key driver of disease (FIG. 3Aa), including ageing-associated diseases, and has been described as a prominent risk factor for morbidity and death95–97.”
§ NAD+ metabolism and its roles in cellular processes during ageing > NAD+-dependent mechanisms in ageing > Deregulation of immune cell function
What the sources say
- Not checked yetcites [95] Franceschi, C., Garagnani, P., Parini, P., Giuliani, C. & Santoro, A. Inflammaging: a new immune-metabolic viewpoint for age-related diseases. Nat. Rev. Endocrinol. 14, 576–590 (2018). source
- Not checked yetcites [96] Hotamisligil, G. S. Inflammation, metaflammation and immunometabolic disorders. Nature 542, 177–185 (2017). source
- Not checked yetcites [97] Furman, D. et al. Chronic inflammation in the etiology of disease across the life span. Nat. Med. 25, 1822–1832 (2019). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“This switch in macrophage polarization states in the visceral fat is accompanied by enhanced expression of proinflammatory cytokines, insulin resistance and reduced rates of lipolysis.”
§ NAD+ metabolism and its roles in cellular processes during ageing > NAD+-dependent mechanisms in ageing > Deregulation of immune cell function
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Taken together, these key studies have provided strong evidence and the rationale that targeting NAD+ degradation pathways or boosting NAD+ levels can influence metabolic processes and can be protective against metabolic disease.”
§ NAD+ metabolism and its roles in cellular processes during ageing > NAD+-dependent mechanisms in ageing > Metabolic dysfunction
boostedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“In further support of this model, numerous studies have now shown that mouse models including Parp1-knockout and Cd38-knockout mice, or mice treated with PARP or CD38 inhibitors, have supraphysiological levels of NAD+. They are also protected from obesity, have increased metabolic rates and have (relatively) normal glucose metabolism during high-fat diet conditions and during ageing42,89–91.”
§ NAD+ metabolism and its roles in cellular processes during ageing > NAD+-dependent mechanisms in ageing > Metabolic dysfunction
What the sources say
- Not checked yetcites [42] Camacho-Pereira, J. et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metab. 23, 1127–1139 (2016). This study demonstrates that CD38 expression increases in multiple tissues during aging and that CD38 is a major NADase involved in the ageing-related tissue decline of NAD+ levels. source
- Not checked yetcites [89] Barbosa, M. T. P. et al. The enzyme CD38 (a NAD glycohydrolase, EC 3.2.2.5) is necessary for the development of diet-induced obesity. FASEB J. 21, 3629–3639 (2007). source
- Not checked yetcites [90] Szántó, M. & Bai, P. The role of ADP-ribose metabolism in metabolic regulation, adipose tissue differentiation, and metabolism. Genes Dev. 34, 321–340 (2020). source
- Not checked yetcites [91] Tarragó, M. G. et al. A potent and specific CD38 inhibitor ameliorates age-related metabolic dysfunction by reversing tissue NAD decline. Cell Metab. 27, 1081–1095.e10 (2018). This study demonstrates that the pharmacological inhibition of CD38 reverses age-related NAD+ level decline, improving several physiological and metabolic features. source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“In support of this hypothesis, it has now been demonstrated in mammalian systems that lifespan-extending metabolic manipulations, such as exercise75–77, caloric restriction78, time-restricted feeding and a ketogenic diet79, as well as healthy circadian rhythms1,11 (including regular sleep patterns80), work in part by increasing NAD+ levels, which leads to the activation of sirtuins.”
§ NAD+ metabolism and its roles in cellular processes during ageing > NAD+-dependent mechanisms in ageing > Metabolic dysfunction
What the sources say
- Not checked yetcites [75] Fukuwatari, T., Shibata, K., Ishihara, K., Fushiki, T. & Sugimoto, E. Elevation of blood NAD level after moderate exercise in young women and mice. J. Nutr. Sci. Vitaminol. 47, 177–179 (2001). source
- Not checked yetcites [76] de Guia, R. M. et al. Aerobic and resistance exercise training reverses age-dependent decline in NAD salvage capacity in human skeletal muscle. Physiol. Rep. 7, e14139 (2019). source
- Not checked yetcites [77] Cantó, C. et al. AMPK regulates energy expenditure by modulating NAD metabolism and SIRT1 activity. Nature 458, 1056–1060 (2009). source
- Not checked yetcites [78] Mitchell, S. J. et al. Effects of sex, strain, and energy intake on hallmarks of aging in mice. Cell Metab. 23, 1093–1112 (2016). source
- Not checked yetcites [79] Elamin, M., Ruskin, D. N., Masino, S. A. & Sacchetti, P. Ketogenic diet modulates NAD-dependent enzymes and reduces DNA damage in hippocampus. Front. Cell. Neurosci. 12, 263 (2018). source
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Conversely, increasing cellular NAD+ levels has recently been shown to reduce reductive stress and drive the directionailty of metabolic reactions84.”
§ NAD+ metabolism and its roles in cellular processes during ageing > NAD+-dependent mechanisms in ageing > Metabolic dysfunction
What the sources say
- Not checked yetcites [84] Goodman, R. P. et al. Hepatic NADH reductive stress underlies common variation in metabolic traits. Nature https://doi.org/10.1038/s41586-020-2337-2 (2020). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Additionally, mice receiving a high-fat diet have increased inflammation, which drives decreased expression of NAMPT, and reduced activity of the NAD+ salvage pathway82 (BOX 1), providing a potential mechanistic explanation for why NAD+ levels decline during obesity.”
§ NAD+ metabolism and its roles in cellular processes during ageing > NAD+-dependent mechanisms in ageing > Metabolic dysfunction
What the sources say
- Not checked yetcites [82] Yoshino, J., Mills, K. F., Yoon, M. J. & Imai, S.-I. Nicotinamide mononucleotide, a key NAD intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. Cell Metab. 14, 528–536 (2011). This study demonstrates that NAMPT expression can be dampened in inflammatory settings such as ageing and obesity. source
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“senescent cells upregulate the expression of the NAM salvage enzyme NAMPT (BOX 1) and that the SASP of senescent cells depends on NAD+ levels131”
§ NAD+ metabolism and its roles in cellular processes during ageing > NAD+-dependent mechanisms in ageing > Cellular senescence
What the sources say
- Not checked yetcites [131] Nacarelli, T. et al. NAD metabolism governs the proinflammatory senescence-associated secretome. Nat. Cell Biol. 21, 397–407 (2019). This article demonstrates that the NAD+ salvage pathway is upregulated during cellular senescence and regulates the expression of inflammatory SASP genes. source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“This study and another recent report6,102 suggest that this NAD+ turnover, particularly during the first few hours of macrophage M1 polarization, depends on reactive oxygen species-induced DNA damage and activation of PARP1.”
§ NAD+ metabolism and its roles in cellular processes during ageing > NAD+-dependent mechanisms in ageing > Deregulation of immune cell function
What the sources say
- Not checked yetcites [6] Minhas, P. S. et al. Macrophage de novo NAD synthesis specifies immune function in aging and inflammation. Nat. Immunol. 20, 50–63 (2019). source
- Not checked yetcites [102] Cameron, A. M. et al. Inflammatory macrophage dependence on NAD salvage is a consequence of reactive oxygen species-mediated DNA damage. Nat. Immunol. 20, 420–432 (2019). source
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“ageing macrophages are characterized by impaired de novo synthesis of NAD+, which in itself may impact macrophage function during ageing6”
§ NAD+ metabolism and its roles in cellular processes during ageing > NAD+-dependent mechanisms in ageing > Deregulation of immune cell function
What the sources say
- Not checked yetcites [6] Minhas, P. S. et al. Macrophage de novo NAD synthesis specifies immune function in aging and inflammation. Nat. Immunol. 20, 50–63 (2019). source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Enhanced expression of proinflammatory cytokines may drive a vicious cycle of inflammageing, leading to greater inflammation, enhanced tissue and DNA damage, further activation of major consumers of NAD+, such as CD38 and PARPs, and accelerated physiological age-related decline.”
§ NAD+ metabolism and its roles in cellular processes during ageing > NAD+-dependent mechanisms in ageing > Deregulation of immune cell function
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“suggesting that NAD+ is a critical metabolite for general macrophage activation, and its metabolism is differentially regulated to control distinct biological processes and functions in M1 and M2 macrophages.”
§ NAD+ metabolism and its roles in cellular processes during ageing > NAD+-dependent mechanisms in ageing > Deregulation of immune cell function
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“macrophage polarization can be either tumour promoting (M2) or tumour inhibitory (M1)109”
§ NAD+ metabolism and its roles in cellular processes during ageing > NAD+-dependent mechanisms in ageing > Deregulation of immune cell function
What the sources say
- Not checked yetcites [109] Pathria, P., Louis, T. L. & Varner, J. A. Targeting tumor-associated macrophages in cancer. Trends Immunol. 40, 310–327 (2019). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“supplementation with NR was able to partially rescue this multimorbidity syndrome, in part by reducing inflammation and senescent cell burden132”
§ NAD+ metabolism and its roles in cellular processes during ageing > NAD+-dependent mechanisms in ageing > Cellular senescence
What the sources say
- Not checked yetcites [132] Desdín-Micó, G. et al. T cells with dysfunctional mitochondria induce multimorbidity and premature senescence. Science https://doi.org/10.1126/science.aax0860 (2020). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“NAD+ depletion is reported in several models of accelerated ageing which exhibit neurodegeneration33,134,135, as well as in neuro-degenerative diseases, including Alzheimer disease136, Parkinson disease137,138 and amyotrophic lateral sclerosis (ALS)139.”
§ NAD+ metabolism and its roles in cellular processes during ageing > NAD+-dependent mechanisms in ageing > Neurodegeneration
What the sources say
- Not checked yetcites [33] Scheibye-Knudsen, M. et al. A high-fat diet and NAD+ activate Sirt1 to rescue premature aging in cockayne syndrome. Cell Metab. 20, 840–855 (2014). source
- Not checked yetcites [134] Fang, E. F. et al. Defective mitophagy in XPA via PARP-1 hyperactivation and NAD+/SIRT1 reduction. Cell 157, 882–896 (2014). source
- Not checked yetcites [135] Fang, E. F. et al. NAD replenishment improves lifespan and healthspan in ataxia telangiectasia models via mitophagy and DNA repair. Cell Metab. 24, 566–581 (2016). source
- Not checked yetcites [136] Gong, B. et al. Nicotinamide riboside restores cognition through an upregulation of proliferator-activated receptor-γ coactivator 1α regulated β-secretase 1 degradation and mitochondrial gene expression in Alzheimer’s mouse models. Neurobiol. Aging 34, 1581–1588 (2013). source
- Not checked yetcites [137] Schöndorf, D. C. et al. The NAD+ precursor nicotinamide riboside rescues mitochondrial defects and neuronal loss in iPSC and fly models of Parkinson’s disease. Cell Rep. 23, 2976–2988 (2018). source
- Not checked yetcites [138] Birkmayer, J. G., Vrecko, C., Volc, D. & Birkmayer, W. Nicotinamide adenine dinucleotide (NADH)–a new therapeutic approach to Parkinson’s disease. Comparison of oral and parenteral application. Acta Neurol. Scand. Suppl. 146, 32–35 (1993). source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“a recent study in mice has also shown that cells with dysfunctional mitochondria initiate a proinflammatory programme, with the secretion of proinflammatory cytokines. This was associated with greater senescent cell burden, increased metabolic and physical dysfunction, and premature ageing132.”
§ NAD+ metabolism and its roles in cellular processes during ageing > NAD+-dependent mechanisms in ageing > Cellular senescence
What the sources say
- Not checked yetcites [132] Desdín-Micó, G. et al. T cells with dysfunctional mitochondria induce multimorbidity and premature senescence. Science https://doi.org/10.1126/science.aax0860 (2020). source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Ageing is strongly associated with most neurodegenerative diseases and is accompanied by decreased cellular NAD+ levels in the mammalian brain133.”
§ NAD+ metabolism and its roles in cellular processes during ageing > NAD+-dependent mechanisms in ageing > Neurodegeneration
What the sources say
- Not checked yetcites [133] Zhu, X.-H., Lu, M., Lee, B.-Y., Ugurbil, K. & Chen, W. In vivo NAD assay reveals the intracellular NAD contents and redox state in healthy human brain and their age dependences. Proc. Natl Acad. Sci. 112, 2876–2881 (2015). source
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“One major phenotype of senescent cells and how they are thought to promote disease is the increased expression of inflammatory mediators, mostly cytokines and chemokines, known as the senescence-associated secretory phenotype (SASP), which contributes to impaired tissue homeostasis by interfering with stem cell regeneration, tissue and wound repair and inflammageing125,126”
§ NAD+ metabolism and its roles in cellular processes during ageing > NAD+-dependent mechanisms in ageing > Cellular senescence
What the sources say
- Not checked yetcites [125] Coppé, J.-P. et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol. 6, 2853–2868 (2008).
- Not checked yetcites [126] Basisty, N. et al. A proteomic atlas of senescence-associated secretomes for aging biomarker development. PLoS Biol. 18, e3000599 (2020). This article presents a comprehensive proteomic database of soluble proteins and exosomal SASP factors originating from multiple senescence inducers and cell types. source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“a recent study found that M1 macrophage polarization is associated with enhanced degradation of NAD+ and that inhibiting NAMPT blocks glycolytic shifts in M1 macrophages, limiting proinflammatory responses in vitro and reducing systemic inflammation in vivo in response to sepsis102.”
§ NAD+ metabolism and its roles in cellular processes during ageing > NAD+-dependent mechanisms in ageing > Deregulation of immune cell function
What the sources say
- Not checked yetcites [102] Cameron, A. M. et al. Inflammatory macrophage dependence on NAD salvage is a consequence of reactive oxygen species-mediated DNA damage. Nat. Immunol. 20, 420–432 (2019). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“another group has also independently shown that senescent cells and their SASP activate CD38 expression and promote CD38-dependent NADase activity in macrophages105,106.”
§ NAD+ metabolism and its roles in cellular processes during ageing > NAD+-dependent mechanisms in ageing > Cellular senescence
What the sources say
- Not checked yetcites [105] Chini, C. C. S. et al. CD38 ecto-enzyme in immune cells is induced during aging and regulates NAD+ and NMN levels. Nat. Metab. 2, 1284–1304 (2020). This study, along with Covarrubias et al. (2020), demonstrated that senescent cell burden is linked to tissue NAD+ level decline via CD38+ immune cells. source
- Not checked yetcites [106] Chini, C. et al. The NADase CD38 is induced by factors secreted from senescent cells providing a potential link between senescence and age-related cellular NAD decline. Biochem. Biophys. Res. Commun. 513, 486–493 (2019). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Treating senescent cells with NMN can heighten the SASP, leading to increased chronic inflammation, and can promote the development of inflammation-driven cancers.”
§ NAD+ metabolism and its roles in cellular processes during ageing > NAD+-dependent mechanisms in ageing > Cellular senescence
What the sources say
- Not checked yetcites [131] Nacarelli, T. et al. NAD metabolism governs the proinflammatory senescence-associated secretome. Nat. Cell Biol. 21, 397–407 (2019). This article demonstrates that the NAD+ salvage pathway is upregulated during cellular senescence and regulates the expression of inflammatory SASP genes. source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Recently, it was shown that CD38 levels increase in mammalian tissues with age, and CD38 has been proposed to be the major NAD+-consuming enzyme responsible for the decline in NAD+ levels during ageing42,91.”
§ NAD+ metabolism and its roles in cellular processes during ageing > NAD+-dependent mechanisms in ageing > Cellular senescence
What the sources say
- Not checked yetcites [42] Camacho-Pereira, J. et al. CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metab. 23, 1127–1139 (2016). This study demonstrates that CD38 expression increases in multiple tissues during aging and that CD38 is a major NADase involved in the ageing-related tissue decline of NAD+ levels. source
- Not checked yetcites [91] Tarragó, M. G. et al. A potent and specific CD38 inhibitor ameliorates age-related metabolic dysfunction by reversing tissue NAD decline. Cell Metab. 27, 1081–1095.e10 (2018). This study demonstrates that the pharmacological inhibition of CD38 reverses age-related NAD+ level decline, improving several physiological and metabolic features. source
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“CD38 is emerging as a key enzyme involved in inflammageing and senescence45,105,106, which are strongly associated with neurodegenerative diseases124,128,168,169.”
§ NAD+ metabolism and its roles in cellular processes during ageing > NAD+-dependent mechanisms in ageing > Neurodegeneration
What the sources say
- Not checked yetcites [45] Covarrubias, A. J. et al. Senescent cells promote tissue NAD+ decline during ageing via the activation of CD38+ macrophages. Nat. Metab. 2, 1265–1283 (2020). source
- Not checked yetcites [105] Chini, C. C. S. et al. CD38 ecto-enzyme in immune cells is induced during aging and regulates NAD+ and NMN levels. Nat. Metab. 2, 1284–1304 (2020). This study, along with Covarrubias et al. (2020), demonstrated that senescent cell burden is linked to tissue NAD+ level decline via CD38+ immune cells. source
- Not checked yetcites [106] Chini, C. et al. The NADase CD38 is induced by factors secreted from senescent cells providing a potential link between senescence and age-related cellular NAD decline. Biochem. Biophys. Res. Commun. 513, 486–493 (2019). source
- Not checked yetcites [124] Chen, L. et al. CD38-mediated immunosuppression as a mechanism of tumor cell escape from PD-1/PD-L1 blockade. Cancer Discov. 8, 1156–1175 (2018). source
- Not checked yetcites [128] Bussian, T. J. et al. Clearance of senescent glial cells prevents tau-dependent pathology and cognitive decline. Nature 562, 578–582 (2018). source
- Not checked yetcites [168] Franceschi, C. & Campisi, J. Chronic inflammation (inflammaging) and its potential contribution to age-associated diseases. J. Gerontol. A Biol. Sci. Med. Sci. 69, S4–S9 (2014). source
- Not checked yetcites [169] Zhang, P. et al. Senolytic therapy alleviates Aβ-associated oligodendrocyte progenitor cell senescence and cognitive deficits in an Alzheimer’s disease model. Nat. Neurosci. 22, 719–728 (2019). source
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“during axon degeneration, NMNAT2 axonal transport is blocked, and the axonal pool of the protein is rapidly degraded, leading to a critical depletion of NAD+ in the axon142,143.”
§ NAD+ metabolism and its roles in cellular processes during ageing > NAD+-dependent mechanisms in ageing > Neurodegeneration
What the sources say
- Not checked yetcites [142] Gilley, J. & Coleman, M. P. Endogenous Nmnat2 is an essential survival factor for maintenance of healthy axons. PLoS Biol. 8, e1000300 (2010). source
- Not checked yetcites [143] Loreto, A. et al. Mitochondrial impairment activates the Wallerian pathway through depletion of NMNAT2 leading to SARM1-dependent axon degeneration. Neurobiol. Dis. 134, 104678 (2020). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Multiple cells in the brain, including microglia, astrocytes, neurons and endothelial cells, express CD38 (REFS108,160), and treating microglia and astrocytes with inflammatory cytokines induces CD38 expression163,164.”
§ NAD+ metabolism and its roles in cellular processes during ageing > NAD+-dependent mechanisms in ageing > Neurodegeneration
What the sources say
- Not checked yetcites [108] Tabula Muris Consortium et al. Single-cell transcriptomics of 20 mouse organs creates a Tabula Muris. Nature 562, 367–372 (2018). This is a compendium of single-cell transcriptomic data that comprises more than 100,000 cells from 20 mouse organs and tissues. source
- Not checked yetcites [160] Mrdjen, D. et al. High-dimensional single-cell mapping of central nervous system immune cells reveals distinct myeloid subsets in health, aging, and disease. Immunity 48, 599 (2018). source
- Not checked yetcites [163] Mayo, L. et al. Dual role of CD38 in microglial activation and activation-induced cell death. J. Immunol. 181, 92–103 (2008). source
- Not checked yetcites [164] Banerjee, S. et al. CD38/cyclic ADP-ribose regulates astrocyte calcium signaling: implications for neuroinflammation and HIV-1-associated dementia. J. Neuroimmune Pharmacol. 3, 154–164 (2008). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“the NAD+-consuming enzyme SARM1 is activated by axonal injury and mediates axonal degeneration by promoting NAD+ degradation60.”
§ NAD+ metabolism and its roles in cellular processes during ageing > NAD+-dependent mechanisms in ageing > Neurodegeneration
What the sources say
- Not checked yetcites [60] Gerdts, J., Brace, E. J., Sasaki, Y., DiAntonio, A. & Milbrandt, J. SARM1 activation triggers axon degeneration locally via NAD destruction. Science 348, 453–457 (2015). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“an Alzheimer disease mouse model lacking CD38 (Cd38-knockout mice), which results in elevated NAD+ levels in their brains, shows a milder disease phenotype159.”
§ NAD+ metabolism and its roles in cellular processes during ageing > NAD+-dependent mechanisms in ageing > Neurodegeneration
What the sources say
- Not checked yetcites [159] Blacher, E. et al. Alzheimer’s disease pathology is attenuated in a CD38-deficient mouse model. Ann. Neurol. 78, 88–103 (2015). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Overall, Wlds mouse studies largely show the neuro protective function of the biosynthetic enzymes NMNAT1, NMNAT2 and NMNAT3 (REFS142,150–152) and their protective role in several neurodegenerative disorders, including Parkinson disease153–155.”
§ NAD+ metabolism and its roles in cellular processes during ageing > NAD+-dependent mechanisms in ageing > Neurodegeneration
What the sources say
- Not checked yetcites [142] Gilley, J. & Coleman, M. P. Endogenous Nmnat2 is an essential survival factor for maintenance of healthy axons. PLoS Biol. 8, e1000300 (2010). source
- Not checked yetcites [150] Kitaoka, Y. et al. Axonal protection by Nmnat3 overexpression with involvement of autophagy in optic nerve degeneration. Cell Death Dis. 4, e860 (2013). source
- Not checked yetcites [151] Yahata, N., Yuasa, S. & Araki, T. Nicotinamide mononucleotide adenylyltransferase expression in mitochondrial matrix delays Wallerian degeneration. J. Neurosci. 29, 6276–6284 (2009). source
- Not checked yetcites [152] Pellegatta, M. & Taveggia, C. The complex work of proteases and secretases in wallerian degeneration: beyond neuregulin-1. Front. Cell. Neurosci. 13, 93 (2019). source
- Not checked yetcites [153] Conforti, L., Gilley, J. & Coleman, M. P. Wallerian degeneration: an emerging axon death pathway linking injury and disease. Nat. Rev. Neurosci. 15, 394–409 (2014). source
- Not checked yetcites [154] Williams, P. A. et al. Nicotinamide and WLD act together to prevent neurodegeneration in glaucoma. Front. Neurosci. 11, 232 (2017). source
- Not checked yetcites [155] Brown, K. D. et al. Activation of SIRT3 by the NAD+ precursor nicotinamide riboside protects from noise-induced hearing loss. Cell Metab. 20, 1059–1068 (2014). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“During normal physiological conditions, the NAD+ biosynthetic enzyme nicotinamide mononucleotide adenylyltransferase 2 (NMNAT2) (FIG. 1; BOX 1) is a survival factor in axons, in which it needs to be constantly replenished via anterograde axonal transport due to its rapid turnover142.”
§ NAD+ metabolism and its roles in cellular processes during ageing > NAD+-dependent mechanisms in ageing > Neurodegeneration
What the sources say
- Not checked yetcites [142] Gilley, J. & Coleman, M. P. Endogenous Nmnat2 is an essential survival factor for maintenance of healthy axons. PLoS Biol. 8, e1000300 (2010). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Wallerian degeneration slow (Wlds) mice, which are protected from axonal degeneration, showing absence of SARM1 expression144 and higher neuronal NAD+ levels, owing to the overexpression of a chimeric fusion protein of NMNAT1, which allows its redistribution from the nucleus to the axon, where it can substitute for the activity of NMNAT2 (REFS145,146).”
§ NAD+ metabolism and its roles in cellular processes during ageing > NAD+-dependent mechanisms in ageing > Neurodegeneration
What the sources say
- Not checked yetcites [144] Wang, J. et al. A local mechanism mediates NAD-dependent protection of axon degeneration. J. Cell Biol. 170, 349–355 (2005). source
- Not checked yetcites [145] Araki, T., Sasaki, Y. & Milbrandt, J. Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science 305, 1010–1013 (2004). source
- Not checked yetcites [146] Sasaki, Y., Nakagawa, T., Mao, X., DiAntonio, A. & Milbrandt, J. NMNAT1 inhibits axon degeneration via blockade of SARM1-mediated NAD depletion. eLife 5, e19749 (2016). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“CD38 was also reported to affect social behaviour, as was its homologue CD157 (REFS166,167)”
§ NAD+ metabolism and its roles in cellular processes during ageing > NAD+-dependent mechanisms in ageing > Neurodegeneration
What the sources say
- Not checked yetcites [166] Jin, D. et al. CD38 is critical for social behaviour by regulating oxytocin secretion. Nature 446, 41–45 (2007). source
- Not checked yetcites [167] Higashida, H. et al. An immunohistochemical, enzymatic, and behavioral study of CD157/BST-1 as a neuroregulator. BMC Neurosci. 18, 35 (2017). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Sarm1-knockout mice are protected from axonal degeneration60 and can rescue the severe axon growth defects and perinatal death induced by lack of NMNAT2 (REFS147,148).”
§ NAD+ metabolism and its roles in cellular processes during ageing > NAD+-dependent mechanisms in ageing > Neurodegeneration
What the sources say
- Not checked yetcites [60] Gerdts, J., Brace, E. J., Sasaki, Y., DiAntonio, A. & Milbrandt, J. SARM1 activation triggers axon degeneration locally via NAD destruction. Science 348, 453–457 (2015). source
- Not checked yetcites [147] Gilley, J., Adalbert, R., Yu, G. & Coleman, M. P. Rescue of peripheral and CNS axon defects in mice lacking NMNAT2. J. Neurosci. 33, 13410–13424 (2013). source
- Not checked yetcites [148] Gilley, J., Orsomando, G., Nascimento-Ferreira, I. & Coleman, M. P. Absence of SARM1 rescues development and survival of NMNAT2-deficient axons. Cell Rep. 10, 1974–1981 (2015). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Restoration of NAD+ levels with NAD+ supplements and the overexpression of the two biosynthetic enzymes NAMPT and NMNAT1 were found to prevent axon degeneration60,146.”
§ NAD+ metabolism and its roles in cellular processes during ageing > NAD+-dependent mechanisms in ageing > Neurodegeneration
What the sources say
- Not checked yetcites [60] Gerdts, J., Brace, E. J., Sasaki, Y., DiAntonio, A. & Milbrandt, J. SARM1 activation triggers axon degeneration locally via NAD destruction. Science 348, 453–457 (2015). source
- Not checked yetcites [146] Sasaki, Y., Nakagawa, T., Mao, X., DiAntonio, A. & Milbrandt, J. NMNAT1 inhibits axon degeneration via blockade of SARM1-mediated NAD depletion. eLife 5, e19749 (2016). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“NMN treatment significantly increased NAD+ levels and the maximum lifespan also in a mouse model of ataxia telangiectasia135.”
§ NAD+ metabolism and its roles in cellular processes during ageing > Therapeutic targeting of NAD+ level decline > Dietary supplementation
What the sources say
- Not checked yetcites [135] Fang, E. F. et al. NAD replenishment improves lifespan and healthspan in ataxia telangiectasia models via mitophagy and DNA repair. Cell Metab. 24, 566–581 (2016). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“NMN enhances mitochondrial function in various organs, including skeletal muscle201, kidney202–204, liver203, heart205, eyes206, brain161 and the cardiovascular system207, and can mitigate oxidative stress in the vasculature208, including improvements in neurovascular coupling responses in the aged cortex of the brain209.”
§ NAD+ metabolism and its roles in cellular processes during ageing > Therapeutic targeting of NAD+ level decline > Dietary supplementation
What the sources say
- Not checked yetcites [201] Gomes, A. P. et al. Declining NAD+ induces a pseudohypoxic state disrupting nuclear-mitochondrial communication during aging. Cell 155, 1624–1638 (2013). source
- Not checked yetcites [202] Sims, C. A. et al. Nicotinamide mononucleotide preserves mitochondrial function and increases survival in hemorrhagic shock. JCI Insight 3, e120182 (2018).
- Not checked yetcites [203] Uddin, G. M., Youngson, N. A., Sinclair, D. A. & Morris, M. J. Head to head comparison of short-term treatment with the NAD+ precursor nicotinamide mononucleotide (NMN) and 6 weeks of exercise in obese female mice. Front. Pharmacol. 7, 258 (2016). source
- Not checked yetcites [204] Guan, Y. et al. Nicotinamide mononucleotide, an NAD precursor, rescues age-associated susceptibility to AKI in a sirtuin 1–dependent manner. J. Am. Soc. Nephrol. 28, 2337–2352 (2017). source
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“One potential explanation for this discrepancy is that NAM influences NAD+ functions directly and indirectly.”
§ NAD+ metabolism and its roles in cellular processes during ageing > Therapeutic targeting of NAD+ level decline > Dietary supplementation
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
In the paper
“there have been more phase I clinical trials using NR than those using NMN, and these have provided conflicting results.”
§ NAD+ metabolism and its roles in cellular processes during ageing > Therapeutic targeting of NAD+ level decline
What the sources say
- Not checked yetcites TABLE 2
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“One trial showed that short-term NR administration has some beneficial effects in healthy elderly individuals185, and another showed positive results in patients with ALS93,186,187.”
§ NAD+ metabolism and its roles in cellular processes during ageing > Therapeutic targeting of NAD+ level decline
What the sources say
- Not checked yetcites [185] Martens, C. R. et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD in healthy middle-aged and older adults. Nat. Commun. 9, 1286 (2018).
- Not checked yetcites [93] Dollerup, O. L. et al. Effects of nicotinamide riboside on endocrine pancreatic function and incretin hormones in nondiabetic men with obesity. J. Clin. Endocrinol. Metab. 104, 5703–5714 (2019). source
- Not checked yetcites [186] Dollerup, O. L. et al. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. Am. J. Clin. Nutr. 108, 343–353 (2018). source
- Not checked yetcites [187] de la Rubia, J. E. et al. Efficacy and tolerability of EH301 for amyotrophic lateral sclerosis: a randomized, double-blind, placebo-controlled human pilot study. Amyotroph. Lateral Scler. Frontotemporal Degener. 20, 115–122 (2019). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“From the findings taken together, there is growing evidence that NAD+ is a central metabolite for maintaining a healthy nervous system and can impact the biology of multiple brain cell types”
§ NAD+ metabolism and its roles in cellular processes during ageing > NAD+-dependent mechanisms in ageing > Neurodegeneration
hedgedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“long-term (1-year) feeding of mice with NMN starting at 5 months of age increased whole-body insulin sensitivity, energy metabolism and physical activity and improved lipid profiles with no obvious toxic effects199.”
§ NAD+ metabolism and its roles in cellular processes during ageing > Therapeutic targeting of NAD+ level decline > Dietary supplementation
What the sources say
- Not checked yetcites [199] Mills, K. F. et al. Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. Cell Metab. 24, 795–806 (2016). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Aside from being a direct NAD+ precursor in the salvage pathway, NAM is also a by-product of NAD+ catabolism, and at high millimolar concentrations it has been shown to act as a feedback inhibitor for NAD+-dependent enzymes, such as PARPs193 and sirtuins194 in vitro.”
§ NAD+ metabolism and its roles in cellular processes during ageing > Therapeutic targeting of NAD+ level decline > Dietary supplementation
What the sources say
- Not checked yetcites [193] Saldeen, J., Tillmar, L., Karlsson, E. & Welsh, N. Nicotinamide- and caspase-mediated inhibition of poly(ADP-ribose) polymerase are associated with p53-independent cell cycle (G2) arrest and apoptosis. Mol. Cell. Biochem. 243, 113–122 (2003). source
- Not checked yetcites [194] Avalos, J. L., Bever, K. M. & Wolberger, C. Mechanism of sirtuin inhibition by nicotinamide: altering the NAD+ cosubstrate specificity of a Sir2 enzyme. Mol. Cell 17, 855–868 (2005). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“Augmentation of NAD+ levels has shown efficacy in a variety of mouse models of human diseases (TABLE 1), leading to numerous clinical trials of NAD+ boosters in humans during ageing (TABLE 2).”
§ NAD+ metabolism and its roles in cellular processes during ageing > Therapeutic targeting of NAD+ level decline
What the sources say
- Not checked yetcites TABLE 1
- Not checked yetcites TABLE 2
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“long-term administration of NAM prevented disease related to a high-fat diet, promoting healthspan, but it did not have significant effects on lifespan200.”
§ NAD+ metabolism and its roles in cellular processes during ageing > Therapeutic targeting of NAD+ level decline > Dietary supplementation
What the sources say
- Not checked yetcites [200] Mitchell, S. J. et al. Nicotinamide improves aspects of healthspan, but not lifespan, in mice. Cell Metab. 27, 667–676.e4 (2018). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“an increase in NAM level leads to a proportional increase of NAM methylation. This in turn affects cellular availability of methyl groups, which are important for DNA methylation and gene expression modulation (BOX 2).”
§ NAD+ metabolism and its roles in cellular processes during ageing > Therapeutic targeting of NAD+ level decline > Dietary supplementation
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“to date the clinical trials evaluating the pharmacokinetics and toxicology of NAD+ precursors have primarily demonstrated that NMN and NR administration is safe and can efficiently increase NAD+ levels in healthy volunteers (TABLE 2).”
§ NAD+ metabolism and its roles in cellular processes during ageing > Therapeutic targeting of NAD+ level decline
What the sources say
- Not checked yetcites TABLE 2
boosteddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“NAD+ replenishment, using NR and/or NMN, has also been effective in delaying progeroid phenotype and extending lifespan in relevant C. elegans models of xeroderma pigmentosum group A, ataxia telangiectasia and Cockayne syndrome33,134,135 and in a worm model of Werner syndrome (a progeroid disease)196.”
§ NAD+ metabolism and its roles in cellular processes during ageing > Therapeutic targeting of NAD+ level decline > Dietary supplementation
What the sources say
- Not checked yetcites [33] Scheibye-Knudsen, M. et al. A high-fat diet and NAD+ activate Sirt1 to rescue premature aging in cockayne syndrome. Cell Metab. 20, 840–855 (2014). source
- Not checked yetcites [134] Fang, E. F. et al. Defective mitophagy in XPA via PARP-1 hyperactivation and NAD+/SIRT1 reduction. Cell 157, 882–896 (2014). source
- Not checked yetcites [135] Fang, E. F. et al. NAD replenishment improves lifespan and healthspan in ataxia telangiectasia models via mitophagy and DNA repair. Cell Metab. 24, 566–581 (2016). source
- Not checked yetcites [196] Fang, E. F. et al. NAD augmentation restores mitophagy and limits accelerated aging in Werner syndrome. Nat. Commun. 10, 5284 (2019).
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“the NAD+ precursors NR and NMN improve neuronal cell health, memory and cognitive function in rat and mouse models of Alzheimer disease136,161,175–180, and also showed neuroprotective properties in Drosophila melanogaster models of Parkinson disease181,182 and in mouse models of ALS139.”
§ NAD+ metabolism and its roles in cellular processes during ageing > NAD+-dependent mechanisms in ageing > Neurodegeneration
What the sources say
- Not checked yetcites [136] Gong, B. et al. Nicotinamide riboside restores cognition through an upregulation of proliferator-activated receptor-γ coactivator 1α regulated β-secretase 1 degradation and mitochondrial gene expression in Alzheimer’s mouse models. Neurobiol. Aging 34, 1581–1588 (2013). source
- Not checked yetcites [161] Long, A. N. et al. Effect of nicotinamide mononucleotide on brain mitochondrial respiratory deficits in an Alzheimer’s disease-relevant murine model. BMC Neurol. 15, 19 (2015).
- Not checked yetcites [175] Hou, Y. et al. NAD supplementation normalizes key Alzheimer’s features and DNA damage responses in a new AD mouse model with introduced DNA repair deficiency. Proc. Natl Acad. Sci. USA 115, E1876–E1885 (2018). source
- Not checked yetcites [176] Yao, Z., Yang, W., Gao, Z. & Jia, P. Nicotinamide mononucleotide inhibits JNK activation to reverse Alzheimer disease. Neurosci. Lett. 647, 133–140 (2017). source
- Not checked yetcites [177] Wang, X., Hu, X., Yang, Y., Takata, T. & Sakurai, T. Nicotinamide mononucleotide protects against β-amyloid oligomer-induced cognitive impairment and neuronal death. Brain Res. 1643, 1–9 (2016). source
- Not checked yetcites [178] Chi, Y. & Sauve, A. A. Nicotinamide riboside, a trace nutrient in foods, is a vitamin B3 with effects on energy metabolism and neuroprotection. Curr. Opin. Clin. Nutr. Metab. Care 16, 657–661 (2013). source
- Not checked yetcites [179] Sorrentino, V. et al. Enhancing mitochondrial proteostasis reduces amyloid-β proteotoxicity. Nature 552, 187–193 (2017). source
- Not checked yetcites [180] Fang, E. F. et al. Mitophagy inhibits amyloid-β and tau pathology and reverses cognitive deficits in models of Alzheimer’s disease. Nat. Neurosci. 22, 401–412 (2019). source
- Not checked yetcites [181] Lehmann, S., Loh, S. H. Y. & Miguel Martins, L. Enhancing NAD salvage metabolism is neuroprotective in a PINK1 model of Parkinson’s disease. Biol. Open 6, 141–147 (2017). source
- Not checked yetcites [182] Jia, H. et al. High doses of nicotinamide prevent oxidative mitochondrial dysfunction in a cellular model and improve motor deficit in a Drosophila model of Parkinson’s disease. J. Neurosci. Res. 86, 2083–2090 (2008). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“NMN supplementation also increased the number of endothelial cells and improved endothelial cell function by increasing blood flow and endurance in elderly mice by a SIRT1-dependent mechanism210.”
§ NAD+ metabolism and its roles in cellular processes during ageing > Therapeutic targeting of NAD+ level decline > Dietary supplementation
What the sources say
- Not checked yetcites [210] Das, A. et al. Impairment of an endothelial NAD+-H2S signaling network is a reversible cause of vascular aging. Cell 173, 74–89.e20 (2018). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“These beneficial effects of NAD+ precursors could possibly be relevant to humans and are currently being tested in clinical trials (TABLE 2).”
§ NAD+ metabolism and its roles in cellular processes during ageing > Therapeutic targeting of NAD+ level decline > Dietary supplementation
What the sources say
- Not checked yetcites TABLE 2
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“For example, apigenin, a naturally occurring flavonoid, enhances NAD+ levels in human cells and mouse liver tissue, and improves glucose and lipid homeostasis in mouse models of obesity226.”
§ NAD+ metabolism and its roles in cellular processes during ageing > Therapeutic targeting of NAD+ level decline > Inhibition of NAD+ consumption
What the sources say
- Not checked yetcites [226] Escande, C. et al. Flavonoid apigenin is an inhibitor of the NAD+ase CD38: implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndrome. Diabetes 62, 1084–1093 (2013). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Although the study authors did not report lifespan changes directly, they did report activation of the prolongevity AMPK pathway and reduced activation of the mTOR–p70S6K and ERK pathways91.”
§ NAD+ metabolism and its roles in cellular processes during ageing > Therapeutic targeting of NAD+ level decline > Inhibition of NAD+ consumption
What the sources say
- Not checked yetcites [91] Tarragó, M. G. et al. A potent and specific CD38 inhibitor ameliorates age-related metabolic dysfunction by reversing tissue NAD decline. Cell Metab. 27, 1081–1095.e10 (2018). This study demonstrates that the pharmacological inhibition of CD38 reverses age-related NAD+ level decline, improving several physiological and metabolic features. source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“pharmacological inhibition of ACMSD by TES-991 and TES-102524 boosts de novo NAD+ synthesis and SIRT1 activity, ultimately enhancing mitochondrial function in the liver, kidneys and brain of mice216.”
§ NAD+ metabolism and its roles in cellular processes during ageing > Therapeutic targeting of NAD+ level decline > Modulation of NAD+ biosynthesis
What the sources say
- Not checked yetcites [216] Katsyuba, E. et al. De novo NAD synthesis enhances mitochondrial function and improves health. Nature 563, 354–359 (2018). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“a reduced form of NR, NRH, is more stable and potent than NR in increasing intracellular NAD+ content, which occurs through a new metabolic pathway in which adenosine kinase converts NRH into NMNH, which is then oxidized to NMN or further metabolized by NMNATs to produce NADH and then NAD+ (REFS211,212).”
§ NAD+ metabolism and its roles in cellular processes during ageing > Therapeutic targeting of NAD+ level decline > Dietary supplementation
What the sources say
- Not checked yetcites [211] Giroud-Gerbetant, J. et al. A reduced form of nicotinamide riboside defines a new path for NAD biosynthesis and acts as an orally bioavailable NAD precursor. Mol. Metab. 30, 192–202 (2019). source
- Not checked yetcites [212] Yang, Y., Zhang, N., Zhang, G. & Sauve, A. A. NRH salvage and conversion to NAD requires NRH kinase activity by adenosine kinase. Nat. Metab. 2, 364–379 (2020). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“SBI-797812, was proposed as a potent NAMPT activator active in the nanomolar range. This compound increased NAMPT-mediated NMN production in vitro and, importantly, NAD+ levels in cell lines and in vivo214,215.”
§ NAD+ metabolism and its roles in cellular processes during ageing > Therapeutic targeting of NAD+ level decline > Modulation of NAD+ biosynthesis
What the sources say
- Not checked yetcites [214] Wang, G. et al. P7C3 neuroprotective chemicals function by activating the rate-limiting enzyme in NAD salvage. Cell 158, 1324–1334 (2014). source
- Not checked yetcites [215] Gardell, S. J. et al. Boosting NAD with a small molecule that activates NAMPT. Nat. Commun. 10, 3241 (2019). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Clinically, luteolin has neuroprotective effects in children with autism229, although NAD+ levels were not directly assessed in this context.”
§ NAD+ metabolism and its roles in cellular processes during ageing > Therapeutic targeting of NAD+ level decline > Inhibition of NAD+ consumption
What the sources say
- Not checked yetcites [229] Taliou, A., Zintzaras, E., Lykouras, L. & Francis, K. An open-label pilot study of a formulation containing the anti-inflammatory flavonoid luteolin and its effects on behavior in children with autism spectrum disorders. Clin. Ther. 35, 592–602 (2013). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“the neuroprotective agent P7C3 enhances NAMPT activity and boosts NAD+ levels in doxorubicin-treated human cells”
§ NAD+ metabolism and its roles in cellular processes during ageing > Therapeutic targeting of NAD+ level decline > Modulation of NAD+ biosynthesis
What the sources say
- Not checked yetcites [214] Wang, G. et al. P7C3 neuroprotective chemicals function by activating the rate-limiting enzyme in NAD salvage. Cell 158, 1324–1334 (2014). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“NQO1 was shown to be increased by caloric restriction (although it was not sufficient to mediate anti-ageing effects of this dietary intervention)217”
§ NAD+ metabolism and its roles in cellular processes during ageing > Therapeutic targeting of NAD+ level decline > Modulation of NAD+ biosynthesis
What the sources say
- Not checked yetcites [217] Diaz-Ruiz, A. et al. Benefits of caloric restriction in longevity and chemical-induced tumorigenesis are transmitted independent of NQO1. J. Gerontol. A Biol. Sci. Med. Sci. 74, 155–162 (2019). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“In C. elegans, PARP inhibition results in a significant lifespan extension in wild-type worms190, in a model of ataxia telangiectasia135 and under hyperglycaemic conditions221.”
§ NAD+ metabolism and its roles in cellular processes during ageing > Therapeutic targeting of NAD+ level decline > Inhibition of NAD+ consumption
What the sources say
- Not checked yetcites [190] Mouchiroud, L. et al. The NAD+/sirtuin pathway modulates longevity through activation of mitochondrial UPR and FOXO signaling. Cell 154, 430–441 (2013). source
- Not checked yetcites [135] Fang, E. F. et al. NAD replenishment improves lifespan and healthspan in ataxia telangiectasia models via mitophagy and DNA repair. Cell Metab. 24, 566–581 (2016). source
- Not checked yetcites [221] Xia, Q. et al. PARP-1 inhibition rescues short lifespan in hyperglycemic C. elegans and improves GLP-1 secretion in human cells. Aging Dis. 9, 17 (2018). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“NQO1 is commonly overexpressed in most solid tumours in which β-lapachone administration induces imbalance of redox cycle and oxidative stresses220”
§ NAD+ metabolism and its roles in cellular processes during ageing > Therapeutic targeting of NAD+ level decline > Modulation of NAD+ biosynthesis
What the sources say
- Not checked yetcites [220] Morales, J. et al. Review of poly (ADP-ribose) polymerase (PARP) mechanisms of action and rationale for targeting in cancer and other diseases. Crit. Rev. Eukaryot. Gene Expr. 24, 15–28 (2014). source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Although the study authors did not report lifespan changes directly, they did report activation of the prolongevity AMPK pathway and reduced activation of the mTOR–p70S6K and ERK pathways91.”
§ NAD+ metabolism and its roles in cellular processes during ageing > Therapeutic targeting of NAD+ level decline > Inhibition of NAD+ consumption
What the sources say
- Not checked yetcites [91] Tarragó, M. G. et al. A potent and specific CD38 inhibitor ameliorates age-related metabolic dysfunction by reversing tissue NAD decline. Cell Metab. 27, 1081–1095.e10 (2018). This study demonstrates that the pharmacological inhibition of CD38 reverses age-related NAD+ level decline, improving several physiological and metabolic features. source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“PARP1 inhibitors, such as olaparib and rucaparib, are marketed as adjuncts to chemotherapy or monotherapies for cancer222.”
§ NAD+ metabolism and its roles in cellular processes during ageing > Therapeutic targeting of NAD+ level decline > Inhibition of NAD+ consumption
What the sources say
- Not checked yetcites [222] Brown, J. S., Kaye, S. B. & Yap, T. A. PARP inhibitors: the race is on. Br. J. Cancer 114, 713–715 (2016). source
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
The paper relies on this without support.
Ageing reduces the ability to mount an effective adaptive immune response because adaptive immune cell functions change, a process called immunosenescence.
“ageing is characterized by a reduced ability to build an effective adaptive immune response due to altered functions of adaptive immune cells, known as immunosenescence.”
The paper relies on this without support.
Ageing skews immune cell populations, decreasing naive T and B cells, reducing T cell antigen receptor diversity, and increasing virtual memory T cells.
“Ageing leads to an imbalance or skewing of immune cell populations, including decreased levels of naive T and B cells, loss of T cell antigen receptor diversity and an increase in levels of virtual memory T cells.”
The paper relies on this without support.
NAD+-boosting strategies that extend healthspan and lifespan in animal models will also do so in humans.
“The good news is that different NAD+-boosting strategies have been shown to be effective in extending healthspan and lifespan (see the section Therapeutic targeting of NAD+ level decline and TABLE 1).”
“However, the translatability of NAD+-boosting therapies to humans remains the key question to be answered.”
The paper relies on this without support.
Ageing-related diseases will impose substantial societal and economic costs in the coming decades.
“This is particularly important as elderly populations are rising rapidly, and ageing-related diseases are predicted to cause a great deal of societal and economic burden in the coming decades.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Therapeutics targeting NAD+ metabolism have also been proposed as potential treatments for age-related immune decline, since reduced NAD+ levels are associated with impaired mitochondrial function, immune cell metabolic reprogramming, and cell function182.”
From SARS-CoV-2, COVID-19 and the aging immune system (2021) · cites this paper as [182]
In the citing paper
“The levels of NAD decline with ageing in both serum and tissues218.”
From Ageing and rejuvenation of tissue stem cells and their niches (2023) · cites this paper as [218]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ NAD+ metabolism and its roles in cellular processes during ageing > Cellular NAD+ metabolism > NAD+ consumption routes
“however, SARM1 is also expressed by immune cells such as macrophages and T lymphocytes, and regulates their functions63–65.”
§ NAD+ metabolism and its roles in cellular processes during ageing > Cellular NAD+ metabolism > NAD+ consumption routes
“recent evidence revealed that SARM1 is not expressed in macrophages and that the observed chemokine phenotype was due to a background effect of the Sarm1-knockout mouse strain67.”
Citations
Cites
Chronic inflammation in the etiology of disease across the life span
Furman, D., Campisi, J., Verdin, E., Carrera-Bastos, P., Targ, S., Franceschi, C., Ferrucci, L., Gilroy, D. W., Fasano, A., Miller, G. W., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0675-0 · Cited by 4,915
Self-citationLagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin, F., Messadeq, N., Milne, J., Lambert, P., Elliott, P., et al. (2006) · Cell · doi:10.1016/j.cell.2006.11.013 · Cited by 4,057
Chronic Inflammation (Inflammaging) and Its Potential Contribution to Age-Associated Diseases
Franceschi, C., & Campisi, J. (2014) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glu057 · Cited by 3,891
Inflammaging: a new immune–metabolic viewpoint for age-related diseases
Franceschi, C., Garagnani, P., Parini, P., Giuliani, C., & Santoro, A. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0059-4 · Cited by 3,586
Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase
Imai, S.-I., Armstrong, C. M., Kaeberlein, M., & Guarente, L. (2000) · Nature · doi:10.1038/35001622 · Cited by 3,510
AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity
Cantó, C., Gerhart-Hines, Z., Feige, J. N., Lagouge, M., Noriega, L., Milne, J. C., Elliott, P. J., Puigserver, P., & Auwerx, J. (2009) · Nature · doi:10.1038/nature07813 · Cited by 3,300
The Epidemiology of Obesity: A Big Picture
Hruby, A., & Hu, F. B. (2014) · PharmacoEconomics · doi:10.1007/s40273-014-0243-x · Cited by 3,207
Single-cell transcriptomics of 20 mouse organs creates a Tabula Muris
The Tabula Muris Consortium, coordination, O., coordination, L., processing, O. C. A., sequencing, L. P. A., analysis, C. D., annotation, C. T., Writing group, Supplemental text writing group, & Principal investigators (2018) · Nature · doi:10.1038/s41586-018-0590-4 · Cited by 2,842
Inflammation, metaflammation and immunometabolic disorders
Hotamisligil, G. S. (2017) · Nature · doi:10.1038/nature21363 · Cited by 2,570
The multifaceted roles of PARP1 in DNA repair and chromatin remodelling
Ray Chaudhuri, A., & Nussenzweig, A. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.53 · Cited by 1,786
Research works printed but not linked: 1
- Liu, Q., Kriksunov, I. A., Hao, Q., Graeff, R. & Lee, H. C. Acidic residues at the active sites of CD38 and ADP-ribosyl cyclase determine NAAPD synthesis and hydrolysis activities. J. Biol. Chem. https://doi.org/10.2210/pdb2hct/pdb (2006). · DOI
Cited by
Sorted by citations
Items 301–400 of 1,000
Zhao, X., Zhang, M., Wang, J., Ji, K., Wang, Y., Sun, X., Xu, C., Wang, Q., He, N., Song, H., et al. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.10.267 · Cited by 27
NAD+ Metabolism and Interventions in Premature Renal Aging and Chronic Kidney Disease
Chanvillard, L., Tammaro, A., & Sorrentino, V. (2022) · Cells · doi:10.3390/cells12010021 · Cited by 28
Liao, Y., Lai, Y., Xu, H., Gao, L., Fu, X., Wang, X., Wang, Q., Shen, J., Fang, J., & Fang, S. (2023) · Chinese Medicine · doi:10.1186/s13020-023-00755-3 · Cited by 27
Gu, C., Pang, B., Sun, S., An, C., Wu, M., Wang, N., Yuan, Y., & Liu, G. (2023) · Experimental Biology and Medicine · doi:10.1177/15353702231184217 · Cited by 27
Tumor-intrinsic metabolic reprogramming and how it drives resistance to anti-PD-1/PD-L1 treatment
Laubach, K., Turan, T., Mathew, R. S., Wilsbacher, J. L., Engelhardt, J., & Samayoa, J. A. (2023) · Cancer Drug Resistance · doi:10.20517/cdr.2023.60 · Cited by 27
Wang, Y., Xie, F., He, Z., Che, L., Chen, X., Yuan, Y., & Liu, C. (2023) · Small · doi:10.1002/smll.202304433 · Cited by 27
Niacin – a scoping review for Nordic Nutrition Recommendations 2023
Freese, R., & Lysne, V. (2023) · Food & Nutrition Research · doi:10.29219/fnr.v67.10299 · Cited by 27
Nicotinamide N-Methyltransferase (NNMT): A New Hope for Treating Aging and Age-Related Conditions
Li, J., Sun, W.-D., Zhu, X., Mei, Y.-Z., Li, W.-S., & Li, J.-H. (2024) · Metabolites · doi:10.3390/metabo14060343 · Cited by 28
Lai, X., Huang, S., Lin, S., Pu, L., Wang, Y., Lin, Y., Huang, W., & Wang, Z. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-021-02688-w · Cited by 26
Roles of SIRT3 in aging and aging-related diseases
You, Y., & Wang, Z. (2025) · International Journal of Biological Sciences · doi:10.7150/ijbs.115518 · Cited by 26
Ageing and Obesity Shared Patterns: From Molecular Pathogenesis to Epigenetics
Ghanemi, A., Yoshioka, M., & St‐Amand, J. (2021) · Diseases · doi:10.3390/diseases9040087 · Cited by 26
Nishida, T., Naguro, I., & Ichijo, H. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-01007-3 · Cited by 26
Wang, J., Liu, X., Huang, Y., Li, P., Yang, M., Zeng, S., Chen, D., Wang, Q., Liu, H., Luo, K., et al. (2022) · Cell Death Discovery · doi:10.1038/s41420-022-00966-x · Cited by 26
Nicotinamide Mononucleotide Administration Amends Protein Acetylome of Aged Mouse Liver
Luo, C., Ding, W., Zhu, S., Chen, Y., Liu, X., & Deng, H. (2022) · Cells · doi:10.3390/cells11101654 · Cited by 26
Karas, A., Holmannová, D., Borský, P., Fiala, Z., Andrýs, C., Hamáková, K., Švadláková, T., Palička, V., Krejsek, J., Řeháček, V., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10051133 · Cited by 26
NAD+ and Vascular Dysfunction: From Mechanisms to Therapeutic Opportunities
Abdellatif, M., Bugger, H., Kroemer, G., & Sedej, S. (2022) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2022.11.2.111 · Cited by 26
Zhou, Y., Xiang, R., Qin, G., Ji, B., Yang, S., Wang, G., & Han, J. H. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.109137 · Cited by 26
Evolving roles of CD38 metabolism in solid tumour microenvironment
Gao, L., Du, X., Li, J., & Qin, F. X.-F. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-02052-6 · Cited by 26
Nicotinamide mononucleotide improves the Alzheimer's disease by regulating intestinal microbiota
Zhao, X., Kong, M., Wang, Y., Mao, Y., Xu, H.-L., He, W., He, Y., & Gu, J. (2023) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2023.05.075 · Cited by 26
Advances in the Synthesis and Physiological Metabolic Regulation of Nicotinamide Mononucleotide
Zheng, C., Li, Y., Wu, X., Gao, L., & Chen, X. (2024) · Nutrients · doi:10.3390/nu16142354 · Cited by 26
Amyotrophic lateral sclerosis alters the metabolic aging profile in patient derived fibroblasts
Gerou, M., Hall, B., Woof, R., Allsop, J., Kolb, S. J., Meyer, K., Shaw, P. J., & Allen, S. P. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.04.013 · Cited by 26
Benjamin, C., & Crews, R. (2024) · Metabolites · doi:10.3390/metabo14060341 · Cited by 25
Transporters in vitamin uptake and cellular metabolism: impacts on health and disease
Yuan, Y., & Chen, L. (2025) · Life Metabolism · doi:10.1093/lifemeta/loaf008 · Cited by 25
Diaconescu, B. I., Dumitru, A. V., Tătaru, C. P., Toader, C., Șerban, M., Covache-Busuioc, R.-A., & Eva, L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262210835 · Cited by 25
Progresses in both basic research and clinical trials of NAD+ in Parkinson’s disease
Maria Jose Perez, J., Baden, P., & Deleidi, M. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111499 · Cited by 26
The Less We Eat, the Longer We Live: Can Caloric Restriction Help Us Become Centenarians?
Dakic, T. B., Jevdjovic, T. V., Vujovic, P. Z., & Mladenović, A. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126546 · Cited by 25
Lu, J., Wang, M., Chen, Y., Song, H., Wen, D., Tu, J., Guo, Y., & Liu, Z. (2022) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2022.110294 · Cited by 25
Harnessing enzyme cofactors and plant metabolism: an essential partnership
da Fonseca‐Pereira, P., Batista, R. D. C. M., Araújo, W. L., & Nunes‐Nesi, A. (2023) · The Plant Journal · doi:10.1111/tpj.16167 · Cited by 25
Zhao, G., Yang, X.-Y., Zhang, C., Dong, W., Dong, F., Zhang, J., Chen, X.-Y., Yao, R.-Q., Xiao, Z., Chen, L., et al. (2023) · Shock · doi:10.1097/shk.0000000000002153 · Cited by 25
Yamaguchi, S., Irie, J., Mitsuishi, M., Uchino, Y., Nakaya, H., Takemura, R., Inagaki, E., Kosugi, S., Okano, H., Yasui, M., et al. (2024) · Endocrine Journal · doi:10.1507/endocrj.ej23-0431 · Cited by 25
Unlocking Longevity with GLP-1: A Key to Turn Back the Clock?
Chavda, V. P., Balar, P. C., Vaghela, D. A., & Dodiya, P. (2024) · Maturitas · doi:10.1016/j.maturitas.2024.108028 · Cited by 24
Zhao, M., Li, J., Li, Z., Yang, D., Wang, D., Sun, Z., Wen, P., Gou, F., Dai, Y., Ji, Y., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179707 · Cited by 24
Nicotinamide N-methyltransferase (NNMT): A key enzyme in cancer metabolism and therapeutic target
Sun, W.-D., Zhu, X., Li, J., Mei, Y.-Z., Li, W.-S., & Li, J.-H. (2024) · International Immunopharmacology · doi:10.1016/j.intimp.2024.113208 · Cited by 24
Ahmed, A., Iaconisi, G. N., Molfetta, D. D., Coppola, V., Caponio, A., Singh, A., Bibi, A., Capobianco, L., Palmieri, L., Dolce, V., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms26010092 · Cited by 24
Assalve, G., Lunetti, P., Rocca, M. S., Cosci, I., Nisio, A. D., Ferlin, A., Zara, V., & Ferramosca, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26030993 · Cited by 24
Wang, S., Qin, L., Liu, F., & Zhang, Z. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02169-0 · Cited by 24
Cognitive dysfunction in chemobrain: Molecular mechanisms and therapeutic implications
Kim, H., Rashid, M. A., Poleschuk, M., Ullah, F., Lee, S., Kim, S., Qin, B., Zheng, X., & Jang, M.-H. (2025) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2025.118581 · Cited by 25
The Role of Calorie Restriction in the Prevention of Cardiovascular Disease
Perry, C. A., & Gadde, K. M. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-00999-8 · Cited by 24
Modulation of Oxidative Stress-Induced Senescence during Non-Alcoholic Fatty Liver Disease
Pedroza-Díaz, J., Arroyave-Ospina, J. C., Salas, S. S., & Moshage, H. J. (2022) · Antioxidants · doi:10.3390/antiox11050975 · Cited by 27
Tang, S., Sanz, M. G., Smith, O., Krämer, A., Egbase, D., Caton, P., Knapp, S., & Butterworth, S. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.07.016 · Cited by 24
Innate immunity dysregulation in aging eye and therapeutic interventions
Das, S., Ahmad, Z., Suryawanshi, A. S., & Kumar, A. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101768 · Cited by 24
Oxidative degradation of dihydrofolate reductase increases CD38-mediated ferroptosis susceptibility
Ma, Y., Yi, M., Wang, W., Liu, X., Wang, Q., Liu, C., Chen, Y., & Deng, H. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-05383-7 · Cited by 24
NMNAT2: An important metabolic enzyme affecting the disease progression
Li, W., Gao, M., Hu, C., Chen, X., & Zhou, Y. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114143 · Cited by 24
New Insights into the Genetics and Epigenetics of Aging Plasticity
Zhang, J., Wang, S., & Liu, B. (2023) · Genes · doi:10.3390/genes14020329 · Cited by 25
Duan, H., Yu, Q., Ni, Y., Li, J., & Fan, L. (2023) · Foods · doi:10.3390/foods12040859 · Cited by 24
Purhonen, J., Banerjee, R., Wanne, V., Sipari, N., Mörgelin, M., Fellman, V., & Kallijärvi, J. (2023) · Nature Communications · doi:10.1038/s41467-023-38027-1 · Cited by 24
Nicotinamide Adenine Dinucleotide Deficiency and Its Impact on Mammalian Development
Dunwoodie, S. L., Bozon, K., Szot, J. O., & Cuny, H. (2023) · Antioxidants and Redox Signaling · doi:10.1089/ars.2023.0349 · Cited by 24
Cros, C., Cannelle, H., Laganier, L., Grozio, A., & Canault, M. (2021) · Food and Chemical Toxicology · doi:10.1016/j.fct.2021.112060 · Cited by 23
Self-citationSuntornsaratoon, P., Antonio, J. M., Flores, J., Upadhyay, R., Veltri, J., Bandyopadhyay, S., Dadala, R., Kim, M., Liu, Y., Balasubramanian, I., et al. (2024) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2024.04.003 · Cited by 23
Pathobiochemistry of Aging and Neurodegeneration: Deregulation of NAD+ Metabolism in Brain Cells
Kolotyeva, N. A., Groshkov, A. A., Rozanova, N. A., Berdnikov, A. K., Novikova, S. V., Komleva, Y. K., Salmina, A. B., Illarioshkin, S. N., & Пирадов, М. А. (2024) · Biomolecules · doi:10.3390/biom14121556 · Cited by 24
Prokopidis, K., Moriarty, F., Bahat, G., McLean, J., Church, D. D., & Patel, H. P. (2025) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.13799 · Cited by 23
Mir, F. A., Lark, A. R. S., & Nehs, C. J. (2025) · Frontiers in Aging · doi:10.3389/fragi.2025.1605070 · Cited by 23
Zu, Y., Wu, C., Li, F., Yao, H., Xia, Y., Zhang, R., Li, L., Chen, S., Shi, Q., Xi, S., et al. (2025) · Molecular Cell · doi:10.1016/j.molcel.2025.05.022 · Cited by 24
Zheng, J., Wang, S., Sun, J., & Lv, J. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27041653 · Cited by 23
Sirtuin Family and Diabetic Kidney Disease
Bian, C., & Ren, H. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.901066 · Cited by 23
Alfatah, M., & Eisenhaber, F. (2022) · GeroScience · doi:10.1007/s11357-022-00598-0 · Cited by 23
Identification of NAPRT Inhibitors with Anti-Cancer Properties by In Silico Drug Discovery
Ghanem, M. S., Caffa, I., Río, A. D., Franco, J., Parenti, M. D., Monacelli, F., Cea, M., Khalifa, A., Nahimana, A., Duchosal, M. A., et al. (2022) · Pharmaceuticals · doi:10.3390/ph15070848 · Cited by 23
Dhuguru, J., Dellinger, R. W., & Migaud, M. E. (2023) · Nutrients · doi:10.3390/nu15133064 · Cited by 23
NAD+ salvage governs the immunosuppressive capacity of mesenchymal stem cells
Fang, J., Hou, P., Liu, S., Zuo, M., Liu, Z., Chen, W., Han, Y., Li, Y., Wang, T., Feng, C., et al. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01073-2 · Cited by 23
Cyclophilin D in Mitochondrial Dysfunction: A Key Player in Neurodegeneration?
Coluccino, G., Muraca, V. P., Corazza, A., & Lippe, G. (2023) · Biomolecules · doi:10.3390/biom13081265 · Cited by 23
Therapeutic strategies for glaucoma and optic neuropathies
Lo, J., Mehta, K., Dhillon, A., Huang, Y., Luo, Z., Nam, M., Aldiri, I., & Chang, K. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2023.101219 · Cited by 23
Cells in Atherosclerosis: Focus on Cellular Senescence from Basic Science to Clinical Practice
Molnár, A., Pásztor, D. T., Tarcza, Z., & Merkely, B. P. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417129 · Cited by 23
Macrod1 suppresses diabetic cardiomyopathy via regulating PARP1-NAD+-SIRT3 pathway
Liu, Y., Qiu, H.-L., Xia, H., Feng, Y.-Z., Deng, J.-Y., Yuan, Y., Ke, D., Zhou, H., Che, Y., & Tang, Q. (2024) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01247-2 · Cited by 23
Sugisawa, R., Shanahan, K. A., Davis, G. M., Davey, G. P., & Bowie, A. (2024) · iScience · doi:10.1016/j.isci.2024.109940 · Cited by 23
Nanodelivery Optimization of IDO1 Inhibitors in Tumor Immunotherapy: Challenges and Strategies
Jiang, K., Wang, Q., Chen, X., Wang, X., Gu, X., Feng, S., Wu, J., Shang, H., Ba, X., Zhang, Y., et al. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s458086 · Cited by 23
Targeting NAMPT‐OPA1 for treatment of senile osteoporosis
Bai, C., Tian, B., Zhang, M., Qin, Q., Shi, X., Yang, X., Gao, X., Zhou, X., Shan, H., & Bai, J. (2024) · Aging Cell · doi:10.1111/acel.14400 · Cited by 24
Freeberg, K. A., Craighead, D. H., Martens, C. R., You, Z., Chonchol, M., & Seals, D. R. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.881703 · Cited by 23
Effects of Aging on Glucose and Lipid Metabolism in Mice
Lien, E. C., Vu, N., Westermark, A. M., Danai, L. V., Lau, A. N., Gültekin, Y., Kukurugya, M. A., Bennett, B. D., & Heiden, M. G. V. (2024) · Aging Cell · doi:10.1111/acel.14462 · Cited by 22
Yao, W., Liu, M., Li, Z., Qu, L., Sui, S., Xiang, C., Jiang, L., Wang, S., Liu, G., Chen, Y., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.04.039 · Cited by 22
Liang, K., Zhao, L., Zhang, S., Zheng, L., Zhang, Z., Wang, S., Chen, J., Xu, W., Wang, W., Yang, H., et al. (2025) · Nature Nanotechnology · doi:10.1038/s41565-025-02017-9 · Cited by 22
Ducroq, S., Duplus, E., Grange‐Messent, V., Trivelloni, F., Penalva-Mousset, L., Petropoulos, I., & Mhaouty‐Kodja, S. (2023) · Environmental Pollution · doi:10.1016/j.envpol.2023.121341 · Cited by 22
De novo NAD+ synthesis contributes to CD8+ T cell metabolic fitness and antitumor function
Wan, J., Cheng, C., Hu, J., Huang, H., Han, Q., Jie, Z., Zou, Q., Shi, J., & Yu, X. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113518 · Cited by 22
The use of a systems approach to increase NAD+ in human participants
Henderson, J. D., Quigley, S. N. Z., Chachra, S. S., Conlon, N. J., & Ford, D. (2024) · npj Aging · doi:10.1038/s41514-023-00134-0 · Cited by 22
Caloric restriction, Sirtuins, and cardiovascular diseases
Wei, Z., Yang, B., Wang, H., Lv, S., Chen, H., & Liu, D. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003056 · Cited by 22
Yusri, K., Kumar, S., Fong, S., Gruber, J., & Sorrentino, V. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126793 · Cited by 23
Dynamic Aging: Channeled Through Microenvironment
Tan, Q., Liang, N., Zhang, X., & Li, J. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.702276 · Cited by 25
Sirtfoods: New Concept Foods, Functions, and Mechanisms
Akan, O. D., Qin, D., Guo, T., Lin, Q., & Luo, F. (2022) · Foods · doi:10.3390/foods11192955 · Cited by 22
Lee, D., Tomita, Y., Miwa, Y., Shinojima, A., Ban, N., Yamaguchi, S., Nishioka, K., Negishi, K., Yoshino, J., & Kurihara, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911228 · Cited by 22
ONE-seq: epitranscriptome and gene-specific profiling of NAD-capped RNA
Niu, K., Zhang, J., Ge, S., Li, D., Kunfeng, S., You, Y., Qiu, J., Wang, K., Wang, X., Liu, R., et al. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac1136 · Cited by 22
Kremer, M., Schulze, S., Eisenbruch, N., Nagel, F., Vogt, R., Berndt, L., Dörre, B., Palm, G. J., Hoppen, J., Girbardt, B., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46039-8 · Cited by 21
Nuclear IMPDH2 controls the DNA damage response by modulating PARP1 activity
Espinar, L., García‐Cao, M., Schmidt, A., Kourtis, S., Zapater, A. G., Aranda-Vallejo, C., Ghose, R., Garcia-Lopez, L., Sheraj, I., Lorente, N. P., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53877-z · Cited by 21
Exploiting metabolic vulnerabilities in cancer: From mechanisms to therapeutic opportunities
Xue, Z.-R., Xin, Y.-Y., & Jin, W. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.218067 · Cited by 21
Xie, Z., Zhang, X., Li, Y., & Zhu, R. (2025) · Experimental Gerontology · doi:10.1016/j.exger.2025.112913 · Cited by 21
Wang, J., Xin, Y., Dong, Z., Li, S., & Yang, G. (2025) · Experimental Gerontology · doi:10.1016/j.exger.2025.112974 · Cited by 22
Gao, M.-J., Cui, N., Liu, X., & Wang, X. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102507 · Cited by 21
Nicotinamide riboside supplementation ameliorated post-ovulatory oocyte quality decline
Li, H., Wang, H., Xu, J., Zeng, X., Sun, Y., & Yang, Q. (2022) · Reproduction · doi:10.1530/rep-22-0095 · Cited by 21
Downregulation of Sirt6 by CD38 promotes cell senescence and aging
Zhou, H., Liu, S., Zhang, N., Fang, K., Zong, J., An, Y., & Chang, X. (2022) · Aging · doi:10.18632/aging.204425 · Cited by 21
Kitada, M., Araki, S., & Koya, D. (2023) · Cells · doi:10.3390/cells12040595 · Cited by 21
Zhang, Y., Wang, Y., Lu, S., Zhong, R., Liu, Z., Zhao, Q., & Wang, C. (2023) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.13182 · Cited by 21
Nutrient regulation of development and cell fate decisions
Tu, W. B., Christofk, H. R., & Plath, K. (2023) · Development · doi:10.1242/dev.199961 · Cited by 23
Muhie, S. Y., Gautam, A., Misganaw, B., Yang, R., Mellon, S. H., Hoke, A. V., Flory, J. D., Daigle, B. J., Swift, K., Hood, L., et al. (2023) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2023.07.015 · Cited by 21
Insights into the molecular mechanisms of malnutrition‐associated steatohepatitis: A review
Sharma, V., & Patial, V. (2024) · Liver International · doi:10.1111/liv.15932 · Cited by 21
If the 5’ cap fits (wear it) – Non-canonical RNA capping
Potužník, J. F., & Cahová, H. (2024) · RNA Biology · doi:10.1080/15476286.2024.2372138 · Cited by 21
Current insights and future directions of Li-Fraumeni syndrome
Hosseini, M. (2024) · Discover Oncology · doi:10.1007/s12672-024-01435-w · Cited by 21
Decoding the mechanisms behind second primary cancers
Zeng, M., Lin, A., Jiang, A., Qiu, Z., Zhang, H., Chen, S., Xu, M., Liu, Z., Cheng, Q., Zhang, J., et al. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06151-9 · Cited by 21
Zhang, H., Ya, J., Sun, M., Du, X., Ren, J., & Qu, X. (2025) · Chemical Science · doi:10.1039/d4sc07963a · Cited by 21
Fan, Y., Zhao, H., Lu, L., & Wu, W. (2025) · Nutrients · doi:10.3390/nu17111855 · Cited by 21
NAM protects against cisplatin-induced acute kidney injury by suppressing the PARP1/p53 pathway
Wu, W., Fu, Y., Liu, Z., Shu, S., Wang, Y., Tang, C., Cai, J., & Dong, Z. (2021) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2021.115492 · Cited by 21
Wen, D., Zheng, L., Lǚ, K., & Hou, W.-Q. (2021) · Journal of Experimental Biology · doi:10.1242/jeb.242425 · Cited by 21
Feng, S., Guo, L., Wang, H., Yang, S., & Liu, H. (2023) · Communications Biology · doi:10.1038/s42003-023-04613-8 · Cited by 20
Metadata
- Authors
- Covarrubias, A. J., Perrone, R., Grozio, A., & Verdin, E.
- Affiliations
- Buck Institute for Research on Aging (US)
- Corresponding author
- Verdin, Eric
- Venue
- Nature Reviews Molecular Cell Biology
- Published
- 2020-12-22
- Volume
- 22
- Issue
- 2
- Pages
- 119-141
- ISSN
- 1471-0072 (ISSN-L)
- 1471-0080
- PMC
- PMC7963035
- OpenAlex
- W3115773653
- Cited by
- 1,617
- References
- 281
- Citations by year
- 2026: 403 · 2025: 352 · 2024: 302 · 2023: 233 · 2022: 222 · 2021: 103 · 2020: 2
- FWCI
- 17.40
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Nature Reviews Molecular Cell Biology (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Aging (T32AG000266)
- National Institute of Diabetes and Digestive and Kidney Diseases (R24DK085610)
- Topics
- Health Sciences › Medicine › Geriatrics and Gerontology › Sirtuins and Resveratrol in Medicine
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Keywords
- NAD+ metabolism, aging, sirtuins, CD38, poly(ADP-ribose) polymerase, cellular senescence, DNA repair, chromatin remodeling, immune cell function, healthspan extension, lifespan extension, sarcopenia, frailty, metabolic disorders, cognitive decline
- MeSH terms
- Aging, Animals, Cell Physiological Phenomena, Energy Metabolism, Humans, Mitochondria, NAD, Metabolic Networks and Pathways
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review